1. Novosibirsk State Medical University, Ministry of Health of Russia, Novosibirsk, Russia
2. Research Institute of Internal and Preventive Medicine — Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Science, Novosibirsk, Russia
3. Novosibirsk Regional Clinical Diagnostic Center, Novosibirsk, Russia
4. First Moscow State Medical University named after I. M. Sechenov, Moscow, Russia
5. Moscow Regional Research and Clinical Institute (“MONIKI”), Moscow, Russia

Keywords: gastroesophageal reflux disease, Barrett’s esophagus, hiatal hernia, extraesophageal manifestations of gastroesophageal reflux disease

Abstract: Over the years, Barrett’s esophagus doesn`t lose its relevance to clinicians and researchers. The problem is acute as the disease is considered as a precancerous condition associated with the risk of adenocarcinoma in the lower third of the esophagus. Knowledge of non-esophageal clinical “masks” of gastroesophageal reflux disease (GERD) and timely diagnosis is extremely relevant for Barrett’s esophagus patients with a high risk of its development as well as complex treatment and dynamic observation of these patients. The article describes a clinical case of a 10-year unsuccessful case of a 36-years old man with GERD complicated by Barrett’s esophagus. Different specialists who observed the patient didn`t evaluate patient’s cardiac and otorhinolaryngological complaints as extra-esophageal “masks” of GERD, although there was a bright clinical picture of the disease, repeated instrumental examination, including esophagogastroduodenoscopy. courses of antioxidants, metabolic drugs, vegetocorrectors, local treatment of laryngitis, intraperitoneal instillations were unjustifiably prescribed. This practice underlines the timeless relevance of assessing anamnestic data, clarifying the presence of comorbid conditions to ensure an adequate personalized drug approach.

• References total 28 ⇓ :: .
  1. Ivashkin V. T., Mayev I. V., Trukhmanov A. S. et аl. Diagnostics and treatment of gastroesophageal reflux disease: clinical guidelines of the Russian gastroenterological Association. Ross z gastroenterol gepatol koloproktol 2017; 27(4):75-95
  2. Ivashkin V. T., Mayev I. V., Lapina T. L. et al. Diagnostics and treatment of Helicobacter pylori infection in adults: Clinical guidelines of the Russian gastroenterological association. Ross z gastroenterol gepatol koloproktol 2018; 28(1):55-70. doi: 10.22416/1382-4376-2018-28-1-55-70
  3. Fitzgerald R.C., di Pietro M., Ragunath K. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett esophagus. Gut 2014;63(1): 7-24. doi: 10.1136/gutjnl-2013-305372
  4. Ivashkin V. T., Mayev I. V., Trukhmanov A. S. et аl. Klinicheskie rekomendacii Rossijskoj Gastroehnterologicheasoj Associacii po diagnostike i lecheniyu pishchevoda Barretta, 2014
  5. Zajratyanc O. V., Kononov A. V. Pishchevoda Barretta. Klinicheskie rekomendacii Rossijskogo obshchestva patologoanatomov, 2016
  6. Mikami D.J., Murayama K. M. Physiology and pathogenesis gastroesophageal disease. Surg Clin NortH Am. 2015; 95(3): 515-25. doi: 10.1016/j.suc.2015.02.006
  7. Herregods T., Smout A. J., Sweis R., et al. Pathophysiology of GERD: new understanding anew ear. Neurogastroenterol Motil 2015;27(9): 1202-13. doi: 10.1111/nmo.12611
  8. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol 2013;108:308-328. doi: 10.1038/ajg.2012.444
  9. Weijenborg P.W., van Hoeij F. B., Smout A. J., et al. Accuracy of hiatal hernia detection with esophageal high-resolution manometry. Neurogastroenterol Motil 2014;27(2): 293-9. doi: 10.1111/nmo.12507
  10. Starostin B. Gastroesophageal reflux disease (Part I). Epidemiology, risk factors. Gastroenterologiia Sankt-Peterburga. 2014;1-2:2-14.
  11. Postanovlenie Rospotrebnadzora ot 12.12.2016 № 179, «O preduprezhdenii rasprostraneniya parazitozov, peredayushchihsya cherez rybu i rybnuyu produkciyu, v Rossijskoj Federacii». http://rospotrebnadzor.ru/upload/iblock/8a6/postanovlenie-_179-ot-12-dekabrya-2016.pdf
  12. Saleh C.M., Smout J. P.M., Bredenoord A. J. The diagnosis of the gastroesophageal reflux disease cannot be made with barium esophagograms. Neurogastroenterol Motil 2015;27: 195-200. doi: 10.1111/nmo.12457
  13. Alvarer Herrero L, Curvers WL, van Vilsteren FG, et al. Validation of the Prague C&M ciassification of Barrett esophagus: in clinical practici. Endoscopy. 2013;45:876-82. doi: 10.1055/s-0033-1344952
  14. Tsygankova O. V., Sokolova T. A., Latyntsev L. D. et аl. Cholestasis syndrome in the practice of an internist. RMJ. MEDICAL REVIEW. 2017; 2: 110-112.
  15. Golovanova E. V., Lazebnik L. B. Gastroesophageal reflux disease in elderly: diagnostic features, clinical features, treatment. Clinical gerontology. 2016; 22(1-2):31-36.
  16. Massimo F Piepoli, Arno W Hoes, Stefan Agewall, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR), European Heart Journal, 2016; 37(29):2315-2381. doi: 10.1093/eurheartj/ehw106
  17. Iijima K., Shimosegawa T. Involvement of luminal nitric oxide in the pathogenesis of the gastroesophageal reflux disease spectrum. J Gastroenterol Hepatol. 2014;29(5):898-905. doi: 10.1111/jgh.12548.
  18. Hvid-Jensen F., Pedersen L., Funch-Jensen P., et al. Proton pump inhibitor use may not prevent high-grade dysplasia and oesophageal adenocarcinoma in Barrett’s oesophagus: a nationwide study of 9883 patients. Aliment Pharmacol Ther. 2014; 39(9):984-991. doi: 10.1111/apt.12693
  19. Ness-Jensen E., Hveem K., El-Serag H., et al. Lifestyle intervertion in gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2016;14(2):175-82. doi: 10.1016/j.cgh.2015.04.176
  20. Maev I. V., Andreev D. N., Dicheva D. T. Gastroehzofageal’naya reflyuksnaya bolezn’: ot patogeneza k terapevticheskim aspektam. Consillium medicum. 2013;8:30-34
  21. Yaghoobi M., Farrokhyar F., Yuan Y., et al. Is there an increased risk of GERD after Helicobacter pylori eradication?: a meta-analysis. Am J Gastroenterol. 2010; 105:1007-13 doi: 10.1038/ajg.2009.734.
  22. Qian B, Ma S, Shang L, Qian J, Zhang G. Effects of Helicobacter pylori eradication on gastroesophageal reflux disease. Helicobacter. 2011;16(4):255-65. doi: 10.1111/j.1523-5378.2011.00846.x.
  23. Xie T., Cui X., Zheng H., et al. Meta-analysis: eradication of Helicobacter pylori infection is associated with the development of endoscopic gastroesophageal reflux disease. European Journal of Gastroenterology & Hepatology. 2013; 25 (10): 1195-1205. doi: 10.1097/MEG.0b013e328363e2c7.
  24. Rubenstein JH, Inadomi JM, Scheiman J, et al. Association between Helicobacter pylori and Barrett’s Esophagus, Erosive Esophagitis, and Gastroesophageal Reflux Symptoms. Clin Gastroenterol Hepatol. 2013; 26(13): 1231-47. doi: 10.1016/j.cgh.2013.08.029
  25. Sugano K., Task J., Kuipers E. J., et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut 2015;64(9): 1353-67. doi: 10.1136/gutjnl-2015-309252
  26. Hong S.J., Kim S. W. Helicobacter pylori infection in gastroesophageal reflux disease in the Asian Countries. Gastroenterol Res Pract 2015; 2015: 985249. doi: 10.1155/2015/985249
  27. Malfertheiner P., Megraud F., O Morain C.A, et al. Management of Helicobacter pylori infection - the Maastricht V/ Florence Consensus Report. Gut 2017; 66:(1) 6-30. doi: 10.1136/gutjnl-2016-312288
  28. Lazebnik L. B., Bordin D. S. Diagnostics and Treatment of Helicobacter pylori Infection in Russia: Results of Prospective Observational Program. Effective Pharmacotherapy. 2016;15:12-23.

Full text is published :
Tsygankova O. V., Latyntseva L. D., Batluk T. I., Gaskina T. K., Starichkov A. A., Bueverov A. O. Gastroesophageal reflux disease with non-esophageal manifestations, the formation of Barrett’s esophagus on the background of a hiatal hernia. Experimental and Clinical Gastroenterology. 2019;163(3): 16–23. (In Russ.) DOI: 10.31146/1682-8658-ecg-163-3-16-23
Read & Download full text

1. The Loginov Moscow Clinical Scientifi c Center, 111123 shosse Enthuziastov 86, Moscow, Russia

Keywords: chronic pancreatitis, pancreatic cancer, fibronectin, median of enhancement gradient

Abstract: Aim. To assess significance of serum fibronectin and new approaches of computed tomography for pancreatic cancer and chronic pancreatitis differential diagnosis. Material and methods. Data of 49 patients with pancreatic lesions who underwent multislice computed tomography (MSCT) with intravenous contrast enhancement and serum fibronectin (FN) evaluation in 2018 were analyzed. There were 29 (59.2%) males and 20 (40.8%) female patients, mean age 51.9+13.9 (30-82). All patients divided in 3 groups: 1 - with pancreatic ductal adenocarcinoma (PDAC) - 17 p., 34.6%, 2 - chronic pancreatitis with previous pancreonecrosis (CPPN) - 16 p., 32.7%, 3 - chronic calcifying pancreatitis (CCP) - 16 p., 32.7%. All cases of PDAC were pathologically proved. We calculated median of enhancement gradient between region of interest and intact parenchyma (Мgrad) based on MSCT results. Pearson’s correlation coefficient (rp) was calculated for correlation assessment. Results. We assessed mean Мgrad and mean serum FN rate in all three groups: PDAC - 28.1+2.6, р=0.0001, CPPN - 14.9+2.4, р=0.07, CCP - 13.3+0.7, р = 0.08 for Мgrad, and 239.8+30.1, p=0.8, 243.5+33.8, p=0.7, 227.2+34.3, p=0.8 for serum FN rate, respectively. There was statistically significant strong correlation of Мgrad in patients with PDAC (rp=0.63, p=0.0001). We revealed cut-off point of Мgrad value for PDAC that was 20 (p=0.001). There were no statistically significant correlations of serum FN rate in all groups (PDAC rp=0.04, p=0.8; CPPN rp=0.06, p=0.7; CCP rp= -0.03, p=0.8). Conclusion. Mgrad evaluation based on MSCT is an informative marker for differential diagnosis between PDAC and chronic pancreatitis, high rates of Мgrad positively correlate with PDAC existence. There was no correlation between serum FN rate and existence of PDAC, CPPN or CCP revealed.

• References total 34 ⇓ :: .
  1. Raimondi S., Lowenfels A. B., Morselli-Labate A. M. Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection. Best Practice & Research Clinical Gastroenterology, 2010, no. 24. pp. 349-358. doi: 10.1016/j.bpg.2010.02.007
  2. Pinho A.V., Chantrill L., Rooman I. Chronic pancreatitis: A path to pancreatic cancer. Cancer Letters, 2013, vol. 345, no. 2, pp. 203-209. doi: 10.1016/j.canlet.2013.08.015
  3. Russo A., Rossell R., Rolfo K. (eds). Targeted therapies for solid tumors. A Handbook for moving toward new frontiers in cancer treatment. Moscow, GEOTAR-Media, 2018. 360 p.
  4. Philip P.A., Mooney M., Jaffe D. et al. Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. J. Clin.Oncol., 2009, vol. 27, pp. 5660-5669.
  5. Maitra A., Hruban R. H. Pancreatic cancer. Annual Review of Pathology, 2008, vol. 3, 157-188 pp. doi: 10.1146/annurev.pathmechdis.3.121806. 154305
  6. Tamm E.P., Balachandran A., Bhosale P.R, et al. Imaging of pancreatic adenocarcinoma: update on staging/resectability. Radiol. Clin. North. Am., 2012, no. 50, pp. 407-428. doi: 10.1016/j.rcl.2012.03.008
  7. Kannengiesser K., Mahlke R., Petersen F. et al. Instant evaluation of contrast enhanced endoscopic ultrasound helps to differentiate various solid pancreatic lesions in daily routine. World J. Clin. Cases, 2019, vol. 7, no. 1. pp. 19-27. doi: 10.12998/wjcc.v7.i1.19
  8. Su S.B., Qin S.-Y., Luo W., Jiang H. X. Carbohydrate antigen 19-9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis. World J. Gastroenterol., 2015, vol. 21, no. 14, pp. 4323-4333. doi: 10.3748/wjg.v21.i14.4323
  9. Yagudina L. A., Novozhilova A. A. Immunodiagnosis of tumors. Medical Almanac, 2016, vol. 2, no. 42, pp. 48-51.
  10. Varvanina G. G., Vinokurova L. V., Smirnova A. V., Gulyaev A. S., Dubtsova E. A., Noskova K. K., Bordin D. S. Factors of remodeling of the intercellular matrix in the diagnosis of pancreatic diseases. Gastroenterology of Saint Petersburg, 2017, no. 2. pp. 42-48.
  11. Lew D., Afghani E., Pandol S. Chronic pancreatitis: current status and challenges for prevention and treatment. Dig. Dis. Sci., 2017, vol. 62, pp. 1702-1712. doi: 10.1007/s10620-017-4602-2
  12. Manohar M., Verma A., Venkateshaiah S., Sanders N., Mishra A. Pathogenic mechanisms of pancreatitis. World J. Gastrointest. Pharmacol. Ther., 2017, vol. 8, no. 1, pp. 10-25. doi: 10.4292/wjgpt.v8.i1.10
  13. Mikheev Y. A., Evseev A. V., Kanaki A. V. Structural transformation of the pancreatic duct system in patients with chronic pancreatitis. Hastroenterolohyia, 2017, vol. 57, no. 4., pp. 237-243. doi: 10. 22141./ 2308-2097.51.4.2017.11 9288
  14. Wu X., Wang K., Hua W. et al. Fibronectin induced ITGβ1/FAK-dependent apoptotic pathways determines the fate of degenerative NP cells. Journal of Orthopaedic Research, 2018. Available at: https://onlinelibrary.wiley.com/ doi/abs/10.1002/jor.24169 (Accessed 18.02.2019). doi: 10.1002/jor.24169.
  15. Clemmensen I. Fibronectin and its role in connective tissue diseases. Europ. Journ. Clin. Invest. 2008. vol. 11, no. 3, pp. 145-146.
  16. Man S.F.P., Xing L., Connett J. E. Circulating fibronectin to C-reactive protein ratio and mortality: a biomarker in COPD. Eur. Respir. J., 2008, vol. 32, pp. 1451-1457. doi: 10.1183/09031936.00153207
  17. Matuskova J., Chauhan A. K., Cambien B. et al. Decreased plasma fibronectin leads to delayed thrombus growth in injured arterioles. Arterioscler. Thromb. Vasc. Biol., 2006. vol. 26, pp. 1391-1396.
  18. Mosher D. F. Plasma Fibronectin Concentration: A Risk Factor for Arterial Thrombosis? Arterioscler. Thromb. Vasc. Biol., 2006, vol. 26. pp. 1193-1195.
  19. Shevtsova A., Koval E., Ivanov A. Dynamics of fibronectin fragmentation in patients with myocardial infarction: diagnostical and prognostical value. Ann. Univers. Mariae Curie, 2006, vol. 19, no. 2, pp. 187-190.
  20. Gress T., Menke A., Bachem M. Role of extracellular matrix in pancreatic diseases. Digestion, 1998, vol. 59, no. 6, pp. 625-637.
  21. Torphy R.J., Wang Z., True-Yasaki A., Volmar K. E., Collisson E. A. Stromal content is correlated with tissue site. Contrast retention and survival in pancreatic adenocarcinoma. JCO precision oncology, 2018. Available at: http://ascopubs.org/doi/abs/10.1200/ PO.17.00121 (Accessed 30.01.2019).
  22. Diana A., Wang LM., D’Costa Z. Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma. Oncotarget, 2016, vol. 7, no. 27, pp. 40992-41004. doi: 10.18632/oncotarget.10038
  23. Jiang H., Hegde S., Knolhoff B. L. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat. Med., 2016, no. 22, pp. 851-860. doi: 10.1038/nm.4123
  24. Lalwani H., Mannelli L., Ganeshan D. M., Shanbhogue A. K., Prasad S. R. Uncommon pancreatic tumors and pseudotumors. Abdominal Imaging, 2015, vol. 40. no. 1, pp. 167-180. doi: 10.1007/s00261-014-0189-7
  25. Okum S.D., Lewin D. N. Non-neoplastic lesions that may mimic malignancy. Semin. Diagn. Pathol. 2016, vol. 33, no. 1, pp. 31-42. doi: 10.1053/j.semdp. 2015.09.005
  26. Vinokurova L. V., Dubtsova E. A., Shustova S. G., Varvanina G. G., Nilova T. V., Agafonov M. A. Functional failure of pancreas in patients with chronic pancreatitis different etiology. Effektivnaya farmakoterapiya, 2012, no. 24, pp. 44-49.
  27. Zhang L., Sanagapalli S., Stoita A. Challenges in diagnosis of pancreatic cancer. World J. Gastroenterol. 2018, vol. 24, no. 19, pp. 2047-2060. doi: 10.3748/wjg.v24.i19.2047
  28. Yashina N. I., Karmazanovskiy G. G., Kozlov I. A., Vinokurova L. V. The role of CT criteria for the choice of the method of surgical treatment of chronic pancreatitis. Meditsinskaya vizualizatsiya, 2006, no. 3, pp. 75-87.
  29. Hata H., Mori H., Matsumoto S. Fibrous stroma and vascularity of pancreatic carcinoma: correlation with enhancement patterns on CT. Abdom. Imaging, 2010, no. 35, pp. 172-180. doi: 10.1007/s00261-008-9460-0
  30. Нattori Y., Gabata T., Matsui O., Mochizuki K., Nakanuma Y. Enhancement patterns of pancreatic adenocarcinoma on conventional dynamic multi-detector row CT: correlation with angiogenesis and fibrosis. World journal of gastroenterology, 2009, vol. 15, no. 25, pp. 3114-3121. doi: 10.3748/wjg.15.3114
  31. Topalovski M., Brekken R. A. Matrix control of pancreatic cancer: New insights into fibronectin signaling. Cancer letters, 2015, vol. 381, no. 1, pp. 252-258. doi: 10.1016/j.canlet.2015.12.027
  32. Bendas G., Borsig L. Cancer cell adhesion and metastasis: selectins, integrins, and the inhibitory potential of heparins. Int. J. Cell. Biol., 2012, Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3296185 (Accessed 30.01.2019). doi: 10.1155/2012/676731
  33. Rhim A.D., Oberstein P. E., Thomas D. H., Mirek E. T., … Stanger B. Z. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell. 2014, no. 25, pp. 735-747. doi: 10.1016/j.ccr.2014.04.021
  34. Thomas D., Radhakrishnan P. Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis. Mol. Cancer., 2019, vol. 18, no 1. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341551 (Accessed 30.01.2019). doi:10.1186/s12943-018-0927-5

Full text is published :
Vinokurova L. V., Lesko K. A., Bordin D. S., Dubtsova E. A., Tyulyaeva E. Yu., Varvanina G. G. Research of new approaches of differential diagnosis of pancreatic lesions. Experimental and Clinical Gastroenterology. 2019;163(3): 24–30. (In Russ.) DOI: 10.31146/1682-8658-ecg-163-3-24-30
Read & Download full text

1. FSBEI HE SUSMU MOH Russia, 454092, Russian Federation, Ural Federal District, Chelyabinsk region, Chelyabinsk city, Vorovskogo street, 64

Keywords: chronic pancreatitis, Helicobacter pylori, gastrin, exocrine insuffi ciency

Abstract: Purpose of the study. To assess the state of the acid-producing function of the stomach in patients with varying degrees of functional insufficiency of the pancreas in the presence of Helicobacter pylori-associated gastritis. Materials and methods: 77 patients with chronic pancreatitis and concomitant Helicobacter pylori-associated gastritis were examined. The control group consisted of 56 patients with chronic pancreatitis without Helicobacter pylori-associated gastritis. Diagnosis of chronic pancreatitis was based on anamnestic, clinical data, instrumental studies (MSCT). The exocrine function of the pancreas was assessed by the content of pancreatic elastase in the feces. Diagnosis of H. pylori infection was carried out by the morphological method, urease respiratory test 13C, by immunoblotting. All patients underwent endoscopic examination of the stomach. In some patients, the level of gastrin 17 in the blood was determined. Statistical processing was carried out using SPSS Statistic 17.0 application software packages. Results. Pain syndrome was significantly more frequently observed in H.pylori- positive patients with chronic pancreatitis (93.2%, p = 0.045), while more often epigastric pain was observed (30.7% versus 12.5% of the control group, p = 0.48). In patients with chronic pancreatitis with an intense pain syndrome, in 66.7% of cases, the combination of proteins p26, p19 and p17 with CagA H.pylori was detected. In patients with chronic pancreatitis with concomitant Helicobacter pylori-associated gastritis, the level of gastrin was outside the normal range in 57.1% of cases (control group - 18.2%, p = 0.048) and was below normal in 42.9% of patients. The average value of gastrin in patients of the studied group was lower (3.140 ± 0.802 pmol / l) than in the control group (4.833 ± 1.594 pmol / l, p = 0.045). In patients with exocrine pancreatic insufficiency, the level of gastrin was reduced / increased in 75% of cases (p = 0.014). In patients with severe chronic pancreatitis, gastrin levels were significantly more often not normal (p = 0.041). CagA VacA - positive strains were statistically significantly more frequently detected in patients with chronic alcoholic pancreatitis and correlated with the severity of the disease. Conclusion. Helicobacter pylori infection contributes to a variety of clinical manifestations in patients with chronic pancreatitis. Helicobacter pylori - a positive status in patients with chronic pancreatitis is associated with more intense gastric acid-induced acid production in the stomach. The severity of morphological changes in chronic pancreatitis, as well as exocrine pancreatic insufficiency correlates with CagA- positive strains of Helicobacter pylori and fluctuations in gastrin levels in the digestive period.

• References total 8 ⇓ :: .
  1. Okorokov A. N. Diagnostika boleznej vnutrennih organov: T.1. Diagnostika boleznej organov pishchevareniya [Diagnosis of diseases of internal organs: Vol.1. Diagnosis of diseases of the digestive system.]. M.: Med. lit., 2000, 560 p.
  2. Kucheryavyj YU.A. Infekciya Helicobacter pylori i zabolevaniya podzheludochnoj zhelezy [Helicobacter pylori infection and pancreatic diseases]. Klinicheskaya farmakologiya i terapiya - Clinical pharmacology and therapy. 2004, Vol. 13., no.1, pp. 40-43.
  3. Bharmal S. H., Pendharkar S. A., Singh R. G. et al. Associations between gastrointestinal humoral factors and pancreatic proteolytic enzymes in alcohol-related versus non-alcohol-related pancreatitis. Alcohol. 2018:76:1-10.
  4. Peterson W. L, Barnett С. С, Evans D. J. Jr. et al. Acid secretion and serum gastrin in normal subjects and patients with duodenal ulcer: the role of Helicobacter pylori. Am. J. Gastroenterol. 1993. Vol.88, pp. 2038-2043.
  5. Jaworek J., Bilski J., Jachimczak B. et al. The effects of ammonia on pancreatic enzyme secretion in vivo and in vitro. J. Physiol. Pharmacol. 2000. - Vol.51. - P. 315-332.
  6. Hori Y., Takeyama Y, Shinkai M. et al. Inhibitory effect of vacuolating toxin of Helicobacter pylori on enzyme secretion from rat pancreatic acini. Pancreas. 1999. Vol.18, pp. 324-327.
  7. Solomon Т. Е., Jaworek J. Comparative potencies of chole-cystokinin and gastrin for gastric and pancreatic secretion in dogs. Gastroenterology. 1984. Vol. 86, pp. 1260.
  8. Maev I. V., Samsonov A. A. Bolezni dvenadcatiperstnoj kishki [Diseases of the duodenum]. Moscow, MEDpress-inform, 2005, 512 p.

Full text is published :
Domracheva E. V., Sarsenbaevа A. S. Clinical and functional features of patients with chronic pancreatitis and related helicobacter pylori-associated gastritis. Experimental and Clinical Gastroenterology. 2019;163(3): 31–37. (In Russ.) DOI: 10.31146/1682-8658-ecg-163-3-31-37
Read & Download full text

1. Donetsk National Medical University Ministry of Health of Ukraine, 84404, Donetsk region, Liman, Ukraine
2. “Endotehnomed”, Dnepr, Ukraine

Keywords: pancreas, chronic pancreatitis, histostructure

Abstract: Aim - to study the morphological features of the pancreas in clinical and morphological forms of chronic pancreatitis. Materials and methods. Histological preparations of the pancreas were studied in 60 patients with various forms of chronic pancreatitis. Results. Scant inflammatory infiltration of the pancreatic parenchyma (represented by lymphocytes, plasma cells), atrophic and fibrotic changes, which were characterized by unidirection, were detected. The fibrosis was of two kinds - friable and dense fibrosis, that qualitative state of the connecting tissue at the different forms of chronic pancreatitis. Friable fibrosis has been revealed at patients for mild and moderate chronic pancreatitis and dense - for severe and complete fibrosis. Conclusion The morphological picture of fibrous changes of the pancreas does not depend on the form of the disease and is characterized by a mild degree of fibrosis in 6.6% of patients, moderate - in 20.0%, severe - 16.7%, full fibrosis - 56.7%.

• References total 5 ⇓ :: .
  1. Gubergrits N. B., Khristich T. N. Klinicheskaya pankreatologiya [Clinical pancreatology]. Donetsk, Lebed Publ., 2000, 416 p.
  2. Barbu T., Andren-Sandberg A. Pancreatic diseases in 2008: What are the burning issues? - Cluj-Napoca: Casa Cartii de Stiinta, 2008. 266 p.
  3. Schneider A., Lohr J. M., Singer M. V. The M-ANNHEIM classification of chronic pancreatitis: introduction of a unifying classification system based on a review of previous classifications of the disease. J. Gastroenterol. 2007. Vol. 42, No 2, pp. 101-119.
  4. Stolte M. Chronische Pancreatitis. Verh.Dtsch.Ges.Path., 1987. Vol.71, pp.175
  5. Kobayashi T., Manivel J. C., Bellin V. D., et al. Correlation of pancreatic histopathologis findings and islet in children with chronic pancreatitis undergoing total pancreatectomy and islet autotransplantation. Pancreatology. 2009. no. 9, pp. 57-63.

Full text is published :
Gubergrits N. B., Krylovа О. A., Opikhailo М. C. Features of the pancreatic histostructure in chronic pancreatitis. Experimental and Clinical Gastroenterology.2019;163(3): 38–42. (In Russ.) DOI: 10.31146/1682-8658-ecg-163-3-38-42
Read & Download full text

1. GBUZ Moscow Clinical Research Center named after A. S. Loginov DZM, Moscow, Russia

Keywords: fatty liver disease, diabetes mellitus, correction, receptors, monoclonal antibodies

Abstract: Non-alcoholic fatty liver disease (NAFLD), according to forecasts of the World Health Organization, by 2020 it will take the 1st place among all liver diseases., Liver transplantation in patients with cirrhosis in the outcome of NAFLD already takes 2nd place after liver cirrhosis of viral etiology. In patients with NAFLD, mortality in the 1st month after surgery significantly exceeds this indicator in case of liver cirrhosis of a different etiology, and there is an increased risk of other complications of liver transplantation, such as sepsis, transplant rejection and cardiovascular pathology. Specific diagnostic criteria and standard therapy of NAFLD, in practice, does not exist, most likely the diagnosis of NAFLD - “diagnosis of exclusion.” Despite the high prevalence of NAFLD to date, the problem of its effective therapy has not been solved. None of the drugs used in the treatment of NAFLD has a high evidence base. Correction of body weight, changes in food addiction, physical activity are the most effective measures preventing the development of NAFLD and elimination of those negative metabolic processes that are predictors of development of severe forms of type 2 diabetes and high risks of cardiovascular diseases..

• References total 13 ⇓ :: .
  1. Konrad R.J, Troutt J. S., Cao G. Effects of currently prescribed LDL-Clowering drugs on PCSK9 and implications for the next generation of LDLC-lowering agents. Lipids Health Dis. 2011, № 10, P. 38. 87.
  2. Koren M. J., Giugliano R. P., Raal F. J., et al. Efficacy and safety of longerterm administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the open-label study of longterm evaluation against LDL-C (OSLER) randomized trial. Circulation. 2014, Vol.129, № 2, P. 234-43
  3. Koren M. J., Lundqvist P., Bolognese M., et al. Anti-PCSK9 monotherapy for hypercholesterolemia - the MENDEL-2 randomized, controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol. 2014, № 63(23), P. 2531-40.
  4. Kotowski, I. K., Pertsemlidis, A., Luke, A., Cooper, R. S., Vega, G. L., Cohen, J. C., & Hobbs, H. H. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am J Hum Gen 2006;78(3), 410-422.
  5. Benjannet S., Rhainds D., Essalmani R., et al. NARC-1/PCSK9 and Its natural mutants: Zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem. 2004, № 279 (November (47)), P. 48865-75.
  6. Benn M., Nordestgaard B. G., Grande P., et al. PCSK9 R46L, lowdensity lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. J Am Coll Cardiol. 2010, № 55, P. 2833-42.
  7. Berthold H. K., Seidah N. G., Benjannet S., Gouni-Berthold I. Evidence from a randomized trial that simvastatin, but not ezetimibe, upregulates circulating PCSK9 levels. PloS One. 2013, № 8 - P. 60095.
  8. Blanchet, M., Le, Q. T., Seidah, N. G., & Labonte, P. Statins can exert dual, concentration dependent effects on HCV entry in vitro. Antivir Res 2016; 128: 43-48.
  9. Bridge S.H., Sheridan D. A., Felmlee D. J., et al. PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: evidence for genotype-specific regulation of lipoprotein metabolism. J Hepatol, 2015, № 6 -Р.763-770.
  10. Cui Q., Ju X., Yang T., et al. Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population. Atherosclerosis. 2010, № 213 (2), P. 632-636.
  11. Dadu R. T., Ballantyne C. M. Lipid lowering with PCSK9 inhibitors. Nat. Rev. Cardiol. 2014, Vol. 84, P. 1-13.
  12. Davignon J., Dubuc G., Seidah N. G. The influence of PCSK9 polymorphisms on serum low-density lipoprotein cholesterol and risk of atherosclerosis. Curr Atheroscler Rep. 2010, № 12, P. 308-15.
  13. Zvenigorodskaya L. A. Non-Alcoholic Fatty Liver Disease: Evolution of Concepts, Pathogenetic Accents Approaches to Th erapy. Diffi cult patient. 2015;10–11:37–43.

Full text is published :
Zvenigorodskaya L. A., Khomeriki S. G., Lychkova A. E. Promising methods for the treatment of dyslipidemia in patients with NAFLD. Experimental and Clinical Gastroenterology. 2019;163(3): 81–88. (In Russ.) DOI: 10.31146/1682-8658-ecg-163-3-81-88
Read & Download full text

1. I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
2. Moscow Regional Research and Clinical Institute (“MONIKI”), Moscow, Russia

Keywords: drug damage to the liver, epidemiology, risk factors, treatment

Abstract: Medicinal liver damage (LPP) is one of the main undesirable effects of pharmacotherapy. The emergence of new drugs on the pharmaceutical market, an increase in the number of LPP caused by herbal preparations and biologically active additives, as well as the expansion of the market for immunobiological drugs, make drugs the most important etiological factors for liver damage. For timely diagnosis of LPP, it is necessary to take into account the totality of risk factors, among which, in recent years, significant attention has been paid to biomarkers. The choice of tactics for the management of a patient with LPP is determined by the nature and severity of the disease, the characteristics of the use of a potentially hepatotoxic drug and the individual characteristics of the patient. The appointment of drugs with high hepatotoxic potential sometimes requires a preventive prescription of pathogenetic agents. When using drugs with low hepatotoxic potential, individual monitoring of biochemical parameters is recommended.

• References total 52 ⇓ :: .
  1. Alempijevic T, Zec S, Milosavljevic T. Drug-induced liver injury: do we know everything? World J Hepatol. 2017; 9(10):491-502. doi: 10.4254/wjh.v9.i10.491
  2. Popper H, Rubin E, Cardiol D et al. Drug-induced liver disease: a penalty for progress. Arch Intern Med 1965; 115:128-136.
  3. Chalasani N, Bonkovsky HL, Fontana RJ et al. Drug-induced liver in the USA: a report of 899 instances assessed prospectively. Gastroenterology 2015; 148:1340-1352.
  4. Giordano CM Clinical manifestations and treatment of drug-induced hepatotoxicity. Clin Liver Dis 2013; 17:565-573.
  5. Bjornsson ES, Bergmann OM, Bjornsson HK et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013; 144:1419-1425.
  6. Zimmerman HJ. Hepatotoxocity: The adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, William & Wilkins; 1999.
  7. Lewis JH. The art and science of diagnosing and managing drug-induced liver Injury in 2015 and beyond. Clin Gastroenterol Hepatol. 2015; 13:2173-2189.e8.
  8. Real M, Barnhill MS, Higley C, Rosenberg J, Lewis JH. Drug-iInduced liver injury: highlights of the recent literature. Drug Saf. 2018 Oct 20. doi: 10.1007/s40264-018-0743-2.
  9. Suk KT, Kim DJ, Kim CH et al. A prospective nationwide study of drug-induced liver injury in Korea. Am J Gastroenterol 2012; 107:1380-1387.
  10. Navarro VJ, Barnhart HX, Bonkovsky HL et al. The rising burden of herbal and dietary supplement induced hepatotoxicity in the USA. Hepatology 2013; 58:264A.
  11. Hayashi PH, Barnhart HX, Fontana RJ et al. Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the drug-induced liver injury network (DILIN). Liver Int 2015; 35:1623-1632.
  12. Byeon JH, Kil JH, Ahn YC, Son CG. Systematic review of published data on herb induced liver injury. J Ethnopharmacol. 2019; 233:190-196. doi: 10.1016/j.jep.2019.01.006.
  13. Sgro C, Clinard F, Ouazir K et al. Incidence of drug-induced injuries: a French population-based study. Hepatology 2002; 36:451-455.
  14. Temple R. Hy’s law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf. 2006; 15:241-243.
  15. Lucena MI, Andrade RJ, Kaplowitz N et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and gender. Hepatology 2009; 49:2001-2009.
  16. Hunt CM, Yuen NA, Stirnadel-Farrant HA, Suzuki A. Age-related differences in reporting of drug-associated liver injury: data-mining of WHO Safety Report Database. Regul Toxicol Pharmacol 2014; 70:519-526.
  17. Maltcev S. V., Davydovа V. M., Mansurovа G. S. Drugs damage of the liver in children. International Journal of Pediatrics, Obstetrics and Gynecology. 2013; 3(2):19-27.
  18. Shi Q, Yang X, Greenhaw JJ, Salminen AT, Russotti GM, Salminen WF. Drug-induced liver injury in children: clinical observations, animal models, and regulatory status. Int J Toxicol. 2017; 36(5):365-379. doi: 10.1177/1091581817721675.
  19. Chen M, Borlak J, Tong W. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology 2013; 58:388-396.
  20. Vuppalanchi R, Gotur R, Reddy KR et al. Relationship between characteristics of medications and drug-induced liver disease phenotype and outcome. Clin Gastroenterol Hepatol 2014; 12:1550-1555.
  21. de Abajo FJ, Montero D, Madurga M, García Rodríguez LA. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol 2004; 58:71-80.
  22. Gupta NK, Lewis JH. Review article: the use of potentially hepatotoxic drugs in patients with liver disease. Aliment Pharmacol Ther 2008; 28:1021-1041.
  23. Moctezuma-Velázquez C, Abraldes JG, Montano-Loza AJ. The use of statins in patients with chronic liver disease and cirrhosis. Curr Treat Options Gastroenterol. 2018; 16(2):226-240. doi: 10.1007/s11938-018-0180-4.
  24. Dienstag J. Toxic and drug-induced hepatitis. In: Longo D, Fauci A, Kasper DL, et al, editors. Harrison’s principles of internal medicine. 18th edition. New York: McGraw-Hill; 2011.
  25. Ungo JR. Antituberculous drug-induced hepatoxiti. Role of hepatitis C virus and Human immunodeficiency virus // Am J Respir Crit Care Med. 1998; 157:1871-1876.
  26. Alfirevic A. Predictive genetic testing for drug-induced liver injury: considerations of clinical utility. Clin Pharmacol Ther 2012; 92:376-380.
  27. Urban TJ, Daly AK, Aithal GP. Genetic basis of drug-induced liver injury: present and future. Semin Liver Dis 2014; 34:123-133.
  28. Fan WL, Shiao MS, Hui RC, Su SC, Wang CW, Chang YC, Chung WH. HLA association with drug-induced adverse reactions. J Immunol Res. 2017; 2017:3186328. doi: 10.1155/2017/3186328/
  29. Lucena MI, Molokhia M, Shen Y et al. Susceptibility to amoxicillin-clavulanate induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 2011; 141:338-347.
  30. Weiler S, Merz M, Kullak-Ublick GA. Drug-induced liver injury: the dawn of biomarkers? F1000Prime Rep. 2015; 7:34.
  31. Cosgrove B, Alexopoulos L, Hang T. Cytokine-associated drug toxicity in human hepatocytes is associated with signaling network dysregulation. Mol Biosyst 2010; 6:1195-1206.
  32. Bell L, Vuppalanchi R, Watkins P. Serum proteomic profiling in patients with drug-induced liver injury. Aliment Pharmacol Ther 2012; 35:600-612.
  33. Markova SM, De Marco T, Bendjilali N, Kobashigawa EA, Mefford J, Sodhi J, Le H, Zhang C, Halladay J, Rettie AE, et al. Association of CYP2C9*2 with bosentan-induced liver injury. Clin Pharmacol Ther. 2013; 94:678-686.
  34. Li CM, Zhang JY, Tang YY, Mao YM. Research advances in drug-induced autoimmune hepatitis. Zhonghua Gan Zang Bing Za Zhi 2016; 24(11):874-876.
  35. deLemos AS, Foureau DM, Jackobs C et al. Drug-induced liver injury with autoimmune features Semin Liver Dis 2014; 34(2):194-204.
  36. Stine JG, Northup PG. Autoimmune-like drug-induced liver injury: a review and update for the clinician. Expert Opin Drug Metab Toxicol 2016; 21:1-11.
  37. Cheng R, Cooper A, Kench J et al. Ipilimumab-induced toxicities and the gastroenterologist. J Gastroenterol Hepatol. 2015; 30(4):657-666.
  38. Björnsson ES, Gunnarsson BI, Gröndal G, Jonasson JG, Einarsdottir R, Ludviksson BR, Gudbjörnsson B, Olafsson S. Risk of drug-induced liver injury from tumor necrosis factor antagonists. Clin Gastroenterol Hepatol. 2015; 13(3):602-608. doi: 10.1016/j.cgh.2014.07.062
  39. Zhao SX, Zhang YG, Tan PF. Clinical features of drug-induced autoimmune hepatitis and drug-induced liver injury: a comparative analysis. Zhonghua Gan Zang Bing Za Zhi 2016; 24(4):302-306.
  40. Martínez-Casas OY, Díaz-Ramírez GS, Marín-Zuluaga JI, Muñoz-Maya O, Santos O, Donado-Gómez JH, Restrepo-Gutiérrez JC. Differential characteristics in drug-induced autoimmune hepatitis. JGH Open. 2018; 2(3):97-104. doi: 10.1002/jgh3.12054.
  41. de Boer YS, Kosinski AS, Urban TJ et al. Features of autoimmune hepatitis in patients with drug-induced liver injury. Clin Gastroenterol Hepatol 2017; 15(1):103-112.
  42. Björnsson ES. Hepatotoxicity of statins and other lipid-lowering agents. Liver Int 2017; 37(2):173-178.
  43. Ghabril M, Bonkovsky HL, Kum C et al. Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol. 2013; 11(5):558-564.
  44. Jennings JJ, Mandaliya R, Nakshabandi A, Lewis JH. Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies. Expert Opin Drug Metab Toxicol. 2019; 5:1-14. doi: 10.1080/17425255.2019.1574744.
  45. Watanabe M, Shibuya A. Validity study of a new diagnostic scale for druginduced liver injury in Japan - comparison with two previous scales. Hepatol Res 2004; 30:148-154.
  46. Rumack BH, Bateman DN. Acetaminophen and acetylcysteine dose and duration: past, present and future. Clin Toxicol (Phila) 2012; 50:91-98.
  47. Bari K, Fontana RJ. Acetaminophen overdose: what practitioners need to know. Clin Liver Dis 2014; 4:17-21.
  48. Denise MH. Use of Ursodeoxycholic acid therapy in the treatment of cholestatic liver diseases. US Gastroenterology review 2007; 46-49.
  49. Suraweera D, Rahal H, Jimenez M, Viramontes M, Choi G, Saab S. Treatment of primary biliary cholangitis ursodeoxycholic acid non-responders: A systematic review. Liver Int. 2017; 37(12):1877-1886. doi: 10.1111/liv.13477.
  50. Sola S, Amaral JD, Castro RE et al. Nuclear translocation of UDCA by the glucocorticoid receptor is required to reduce TGFbeta1-induced apoptosis in rat hepatocytes. Hepatology 2005; 42:925-934.
  51. Asgarshirazi M, Shariat M, Dalili H, Keihanidoost Z. Ursodeoxycholic acid can improve liver transaminase quantities in children with anticonvulsant drugs hepatotoxicity: a pilot study. Acta Med Iran. 2015; 53(6):351-355.
  52. Kojima M, Kamoi K, Ukimura O et al. Clinical utility of ursodeoxycholic acid in preventing flutamide-induced hepatopathy in patients with prostate cancer: a preliminary study. Int J Urol 2002; 9:42-46.

Full text is published :
Bueverov A. O., Bueverova E. L. The evolution of ideas about medicinal liver damage. Experimental and Clinical Gastroenterology. 2019;163(3):89–96. (In Russ.) DOI: 10.31146/1682-8658-ecg-163-3-89-96
Read & Download full text

1. Institute of Experimental Medicine, Almazov National Medical Research Centre, 197341, Saint Petersburg, Russian Federation
2. Shevchenko Transnistria State University, 3300, Tiraspol, Moldova
3. Institute of Physiology and Sanocreatology, MD-2028, Chisinau, Moldova
4. Scientifi c Research Center “Probiocode SP”, 143026, Moscow, Russian Federation
5. First Pavlov State Medical University of St. Petersburg, 197022, St. Petersburg, Russia

Keywords: antibiotics, isolated intestinal loop, absorption, monosaccharides, isolated heart, infarct size

Abstract: Aim: we aimed to study the effect of the mixture of three broad-spectrum antimicrobials (amoxicillin, metronidazole, clarithromycin, AMC) on monosaccharide absorption in the isolated intestinal loop and on myocardial tolerance to ischemia-reperfusion injury (IRI). Materials and Methods: experiments were performed on adult male Wistar rats housed in conventional area. Glucose and fructose absorption was studied in the model of in situ isolated intestinal loop according to Thiry-Vella after administration of AMC into the intestinal lumen. Isolated heart studies were done using modified Landendorff setup after oral treatment of the animals with AMC. Results: AMC significantly inhibited glucose absorption in the isolated intestinal loop, mainly due to pronounced reduction of active, sodium-dependent glucose cotransporter 1-mediated transport. AMC also caused inhibition of fructose absorption. The animals treated with AMC showed decreased systolic pressure in the left ventricle up to 20% upon reperfusion, decreased pressure in the left ventricle during global ischemia (by 33-500%), increased coronary flow by 28-82%, and also insignificant trend to greater infarct size. Conclusion: AMC-induced inhibition of glucose and fructose absorption provides evidence for the existence of rapid changes in nutrient absorption, mainly due to inhibition of active transport. AMC treatment also resulted in deterioration of morphological and functional parameters of the isolated heart. The data obtained warrant further studies on the antibiotic-induced associated changes in enterocytes and cardiomyocytes.

• References total 26 ⇓ :: .
  1. Thiemann S., Smit N., Strowig T. Antibiotics and the Intestinal Microbiome: Individual Responses, Resilience of the Ecosystem, and the Susceptibility to Infections.// Curr Top Microbiol Immunol. 2016, № 398, Р. 123-146.
  2. Postler T. S., Ghosh S. Understanding the holobiont: how microbial metabolites affect human health and shape the immune system. Cell Metab. 2017, Vol. 26, Р. 110-130.
  3. Averina O. V., Ermolenko E. I., Ratushniy A. Y., et al. Influence of probiotics on cytokine production in the in vitro and in vivo systems. Medical Immunology (Russia). 2015;17(5):443-454. (In Russ.) https://doi.org/10.15789/1563-0625-2015-5-443-454
  4. Alcalde A. I., Barcina Y., Ilundain A., Larralde J. Effect of amoxicillin on galactose transport across rat small intestine. Drug Nutr Interact. 1987 - Vol. 5, № 2, P. 71-9.
  5. Sanyal S. N., Jamba L., Channan M. Effect of the antiprotozoal agent metronidazole (Flagyl) on absorptive and digestive functions of the rat intestine.Ann Nutr Metab. 1992, Vol. 36 № 4, P. 235-43.
  6. Yihong Qiu, Yisheng Chen, Geoff G. Z. et al. «ed». Developing Solid Oral Dosage Forms. Pharmaceutical Theory and Practice, 2nd Edition, Amsterdam: Аcademic Press, 2017, Р. 1176.
  7. Ugolev A. M., Zaripov B. Z. Metodicheskiye priyemy dlya izucheniya membrannogo pishchevareniya i vsasyvaniya v tonkoy kishke v usloviyakh khronicheskogo eksperimenta na krysakh i nekotorykh drugikh zhivotnykh [Methodologic approaches to studying membrane digestion and absorption in the small intestine during chronic experiments on rats and certain other animals]. Fiziologicheskiy zhurnal SSSR - Physiological Journal of the USSR. 1979, no. 12, pp. 1850-1854.
  8. Ugolev A. M., Zaripov B. Z., Iyezuitova N. N. et al. Osobennosti membrannogo gidroliza i transporta v tonkoy kishke v usloviyakh, blizkikh k fiziologicheskim [Particularities of membrane digestion and transport in the small intestine under physiological conditions]. Biologicheskiye membrany - Biological Membranes, 1984, T.1, no. 10, pp. 997-1018.
  9. Gromova L. V., Kuznetsov V. L., Gruzdkov A. A., Vershinina E. A. Vsasyvaniye glyukozy i galaktozy v tonkoy kishke krys in vivo [Glucose and galactose absorption in the small intestine of rats in vivo] Fiziol Zh Im I M Sechenova - Journal of Physiology of I.M. Sechenov, 1996, vol. 82, no. 3, pp. 46-56.
  10. Fischer J., Chromy V., Voznicek J. Enzymatic determination of glucose. I. Method and optimal reaction conditions. Biochemia clinica Bohemoslovaca. 1981, Vol. 10, №. 1, Р. 41-45.
  11. Ugolev A. M., Iyezuitova N. N. Issledovaniye pishchevaritel'nogo apparata u cheloveka (obzor sovremennykh metodov) [Research of human digestive system (modern methods review)]. Leningrad, Nauka,1969. pp. 192-194.
  12. Korolev D. V., Alexandrov I. V., Galagoudza M. M., Syrensky A. V. et al. Automation of data acquisition and processing in physiological experiments. Regional blood circulation and microcirculation. 2008;7(2):79-84. (Russ)
  13. Minasian S. M., Badrikhanova L. R., Galagudza Ì. Ì., Kurapeev D. I. Comparative assessment of the protective effect of hypothermia, ischemic precondi-tioning and modified cardioplegic solutions against ischemia-reperfusion injury in the isolated rat heart. Regional blood circulation and microcirculation. 2008;7(26):72-78. (Russ)
  14. Karasov W. H. Integrative physiology of transcellular and paracellular intestinal absorption. J. Exp. Biol. 2017, Vol. 220, №. Pt 14, Р. 2495-2501.
  15. Kelett G. L. Sugar absorption in the intestine: the role of GLUT2. Annu. Rev. Nutr. 2008, Vol. 28, P. 35-54 doi: 10.1146/annurev.nutr.28.061807.155518
  16. Patel C., Douard V., Yu S. et al. Transport, metabolism, and endosomal trafficking-dependent regulation of intestinal fructose absorption. FASEB J. 2015, Vol. 29, №.9, Р. 4046-4058.
  17. Poulsen S. B., Fenton R. A., Timo R. Sodium-glucose cotransport. Curr. Opin. Nephrol. Hypertens. 2015, Vol. 24, №. 5, Р. 463-469.
  18. Pappenheimer J. R, Michel C. C. Role of villus microcirculation in intestinal absorption of glucose: coupling of epithelial with endothelial transport. J. Physio. 2003, № 1, Р. 561-574.
  19. Wright E. M, Loo D. D., Hirayama B. A. Biology of human sodium glucose transporters. Physiol Rev. 2011, Vol. 91, №. 2, P. 733-794
  20. Borshcev Yu. Yu., Minasian S. M., Burovenko I. Yu., et al. Influence of probiotic straine. Faecium L3 on myocardial tolerance to ischemia-reperfusion injury in the modelof antibiotic-induced intestinal dysbiosis. Russian Journal of Physiology. 2016;102(11):1323-1332. (Russ)
  21. Gromova L. V., Borshchev Yu. Yu., Ermolenko E. I., et al. Influence of antimicrobial drugs on intestinal digestive enzymes of rats. Vestnik St. Petersburg University. 2012, no. 3, pp. 161-170.
  22. Borshchov Yu. Yu., Gromova L. V., Ermolenko E. I., et al. Responses of peptide hydrolases of the small and largeintestines in rats on the administration of antibiotics. Russian Journal of Physiology. 2012;98(6):724-733. (Russ)
  23. Lam V., Su J., Hsu A., et al. Intestinal Microbial Metabolites Are Linked to Severity of Myocardial Infarction in Rats. PLoS One. 2016, 11(8): e0160840. doi: 10.1371/journal.pone.0160840.
  24. Zhu H, Sun X, Wang D, Hu N, Zhang Y. Doxycycline ameliorates aggregation of collagen and atrial natriuretic peptide in murine post-infarction heart. Eur J Pharmacol. 2015, P. 66-72. doi: 10.1016/j.ejphar.2015.02.026.
  25. Borshchev Yu. Yu., Sinitsa A. V., Zakharchenko M. M., et al. Effect of Antiobiotic-Induced Disbiosis and Its Correction with Probiotics on Myocardial Tolerance to Ischemia-Reperfusion Injury in SPF Rats. Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 166, No. 10, pp. 426-430
  26. Borshchev Yu. Yu., Minasian S. M., Burovenko I. Yu., et al. Antibiotic-induced intestinal dysbiosis and myocardial tolerance to ischemia-reperfusion injury in rats with different microbiological status. Experimental and Clinical Gastroenterology. 2018;158(10): 62-67. DOI: 10.31146/1682-8658-ecg-158-10-62-67

Full text is published :
Burovenko I. Yu., Borshchev Yu. Yu., Minasian S. M., Protsak E. S., Sheptitskii V. A., Galagudza M. M. The study of absorption of monosaccharides in the isolated intestine and resistance of the myocardium to ischemia-reperfusion in rats after administration of antimicrobial agents. Experimental and Clinical Gastroenterology. 2019;163(3): 43–50. (In Russ.) DOI: 10.31146/1682-8658-ecg-163-3-43-50
Read & Download full text

1. “Gamaleya National Research Centre for Microbiology and Immunology”, Ministry of Public Health of Russian Federation, Moscow, Russia
2. “Kinetika Co., Ltd”, Moscow, Russia
3. “Sechenov The First Moscow Medical University”, Ministry of Public Health of Russian Federation, Moscow, Russia
4. “Moscow Institute of Physics and Technology (State Research University)”, Moscow, Russia

Keywords: Helicobacter pylori, cold plasma, bactericidal effect

Abstract: Medicinal liver damage (LPP) is one of the main undesirable effects of pharmacotherapy. The emergence of new drugs on the pharmaceutical market, an increase in the number of LPP caused by herbal preparations and biologically active additives, as well as the expansion of the market for immunobiological drugs, make drugs the most important etiological factors for liver damage. For timely diagnosis of LPP, it is necessary to take into account the totality of risk factors, among which, in recent years, significant attention has been paid to biomarkers. The choice of tactics for the management of a patient with LPP is determined by the nature and severity of the disease, the characteristics of the use of a potentially hepatotoxic drug and the individual characteristics of the patient. The appointment of drugs with high hepatotoxic potential sometimes requires a preventive prescription of pathogenetic agents. When using drugs with low hepatotoxic potential, individual monitoring of biochemical parameters is recommended.

• References total 34 ⇓ :: .
  1. Hooi J.K.Y., Lai W. Y., Ng W. K. et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017;153(2):420-429. https://doi.org/10.1053/j.gastro.2017.04.022
  2. Salama N.R., Hartung M. L., Müller A. Life in the human stomach: persistence strategies of the bacterial pathogen Helicobacter pylori. Nat. Rev. Microbiol. 2013;11(6):385-399. https://doi.org/10.1038/nrmicro3016
  3. Waskito L.A., Salama N. R., Yamaoka Y. Pathogenesis of Helicobacter pylori infection. Helicobacter. 2018;23(Suppl.1: e12516). https://doi.org/10.1111/hel.12516
  4. Venerito M., Vasapolli R., Rokkas T., Malfertheiner P. Gastric cancer: epidemiology, prevention, and therapy. Helicobacter. 2018;23(Suppl.1: e12518). https://doi.org/10.1111/hel.12518
  5. Current European concept in the management of Helicobacter pylori infection. The Maastricht consensus report. The European Helicobacter pylori study group (EHPSG). Gut. 1997; 41(1):8-13.
  6. Malfertheiner P., Megraud F., O’Morain C.A. et al. Management of Helicobacter pylori infection - the Maastricht V / Florence Consensus report. Gut. 2017;66(1):6-30. https://doi.org/10.1136/gutjnl-2016-312288
  7. O’Morain N.R., Dore M. P., O’Connor A.J.P. et al. Treatment of Helicobacter pylori infection in 2018. Helicobacter. 2018;23(Suppl.1: e12519). https://doi.org/10.1111/hel.12519
  8. Lin T-F., Hsu P. I. Second-line rescue treatment of Helicobacter pylori infection: Where are we now? World J. Gastroenterol. 2018;24(40):4548-4553. https://doi.org/10.3748/wjg.v24.i40.4548
  9. Graham D.Y., Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010;59(8):1143-1153. https://doi.org/10.1136/gut.2009.192757
  10. Hathroubi S. et al. Helicobacter pylori biofilm formation and its potential role in pathogenesis. Microbiol. Mol. Biol. Rev. 2018;82(2): pii: e00001-18. https://doi.org/10.1128/MMBR.00001-18
  11. Konstantinova N. D., Zhukhovitsky V. G., Didenko L. V., Andreevskaya S. G. Ultrastructural organization of Helicobacter pylori in natural conditions and under cultivation ex vivo. Bull. Exp. Biol. Med. 2001;131(3):353-356.
  12. Bjorkholm B., Zhukhovitsky V., Lofman C. et al. Helicobacter pylori entry into human gastric epithelial cells: a potential determinant of virulence, persistence, and treatment failures. Helicobacter. 2000;5(3):148-154.
  13. Zhukhovitsky V. G., Kholina E. G., Strakhovskaya M. G. Helicobacter pylori photodynamic inactivation in vitro with zinc octakis (cholinyl) phthalocyanine. Experimental and Clinical Gastroenterology. 2018;154(06):10-15. DOI: 10.31146/1682-8658-ecg-154-6-10-15
  14. Ogasawara K. Helicobacter pylori eradication using a light-emitting diode and methylene blue. Laser. Ther. 2018;27(1):21-25. https://doi.org/10.5978/islsm.18-OR-01
  15. Losurdo G., Cubisino R., Barone M. et al. Probiotic monotherapy and Helicobacter pylori eradication: a systematic review with pooled-data analysis. World J. Gastroenterol. 2018;24(1):139-149. https://doi.org/10.3748/wjg.v24.i1.139
  16. Isbary G., Shimizu T., Li Y. F. et al. Cold atmospheric plasma devices for medical issues. Expert Rev. Med. Devices. 2013;10(3):367-377. https://doi.org/10.1586/erd.13.4.
  17. Sysolyatina E.V. et al. Role of the charged particles in bacterial inactivation by plasma of a positive and negative corona in ambient air. Plasma Processes and Polymers. 2014;11:315-334.
  18. Ermolaeva S.A. et al. Prospects for the use of low-temperature gas plasma as an antimicrobial agent. Vestn. Ross. Akad. Med. Nauk. 2011;10:15-21.
  19. Ermolaeva S.A. et al. Bactericidal effects of non-thermal argon plasma in vitro, in biofilms and in the animal model of infected wounds. J. Med. Microbiol. 2011;60:75-83. https://doi.org/10.1099/jmm.0.020263-0.
  20. Bourke P., Ziuzina D., Han L. et.al. Microbiological interactions with cold plasma. J. Appl. Microbiol. 2017;123(2):308-324. https://doi.org/10.1111/jam.13429.
  21. Zhukhovitsky V. G. Microbiological diagnosis of helicobacteriosis. Experimental and Clinical Gastroenterology. 2008;08:34-45
  22. Schmidt A., Woedtke T. V., Stenzel J. et al. One year follow-up risk assessment in SKH-1 mice and wounds treated with an argon plasma jet. Int. J. Mol. Sci. 2017;18(4): pii: E868. https://doi.org/10.3390/ijms18040868
  23. Bedwell J., Holton J., Vaira D. et al. In vitro killing of Helicobacter pylori with photodynamic therapy. Lancet. 1990;335:1287.
  24. Okamoto T., Nishikawa J., Yanai H. et al. In vitro bactericidal effects of near-ultraviolet light from light-emitting diodes on Helicobacter pylori. Scand. J. Gastroenterol.2013;48:1484-1486. https://doi.org/10.3109/00365521.2013.837953.
  25. Lembo A.J., Ganz R. A., Sheth S. et al. Treatment of Helicobacter pylori infection with intra-gastric violet light phototherapy: a pilot clinical trial. Lasers Surg. Med. 2009;4:337-344. https://doi.org/10.1002/lsm.20770
  26. Ganz R. A., Viveiros J., Ahmad A. et al. Helicobacter pylori in patients can be killed by visible light. Lasers Surg. Med. 2005;36:260-265.
  27. Filatov V. V., Telyatnikova L. I., Dolgikh V. T. Argon-plasmatic coagulation as an alternative to operative intervention. Siberian Med. J. 2010;8:79-81.
  28. Winter J., Nishime T. M.C., Glitsch S. et al. On the development of a deployable cold plasma endoscope. Contrib. Plasma Phys. 2018; - P. 404-414. https://doi.org/10/1002/ctpp.201700127
  29. Hayes S.L., White K. M., Rodgers M. R. Assessment of the effectiveness of low-pressure UV light for inactivation of Helicobacter pylori. Appl. Environ. Microbiol. 2006;72(5):3763-3765. https://doi.org/10.1128/AEM.72.5.3763-3765/2006
  30. Wen Y., Scott D. R., Vagin O. et al. Measurement of internal pH in Helicobacter pylori by using green fluorescent protein Fluorimetry. J. Bacteriol. 2018;200(14): pii: e00178-18. https://doi.org/10.1128/JB.00178-18
  31. Granger D.L., Lehninger A. L. Sites of inhibition of mitochondrial electron transport in macrophage-injured neoplastic cell. J. Cell Biol. 1982;95:527-535.
  32. Nakaki T., Nakayama M., Kato R. Inhibition by nitric oxide and nitric-oxide-producing vasodilators of DNA synthesis in vascular smooth muscle cells. Eur. J. Pharmacol. 1990;189:347-353.
  33. Zhu L., Gunn C., Beckmann J. S. Bactericidal activity of peroxynitrite. Arch. Biochem. Biophys. 1992;298:452-457.
  34. Dykhuizen R.S., Fraser A., McKenzie H. et al. Helicobacter pylori is killed by nitrite under acidic conditions. Gut. 1998;42:334-337.

Full text is published :
Zhukhovitsky V. G., Kazakova M. V., Sysolyatina E. V., Loleit R. A., Lavrikova A. Ya., Sofronov A. V., Ermolaeva S. A. Bactericidal eff ect of low-temperature plasma against Helicobacter pylori in vitro. Experimental and Clinical Gastroenterology. 2019;163(3): 51–57. (In Russ.) DOI: 10.31146/1682-8658-ecg-163-3-51-57
Read & Download full text

1. Moscow Clinical Scientifi c practical Center named after A. S. Loginov, Department of health, city of Moscow, 111123, Moscow, Russia
2. “Research Center of Neurology”, Moscow, Russia
3. FGBOU VPO “Mordovian state University. N. P. Ogarev”, Saransk, Republic of Mordovia, Russia

Keywords: antiplatelet agents, aspirin, gastrointestinal ulcer, antioxidants, carnosine, rats

Abstract: Antiplatelet drugs are widely used for the prevention and treatment of vascular diseases of the heart and brain. The most popular drugs are non-steroidal anti-inflammatory drugs, the first place among which still belongs to acetylsalicylic acid (aspirin) and its derivatives. However, along with high clinical efficacy according to target parameters, these drugs have side effects that lead to damage to the mucous membrane of the gastrointestinal tract (GI). In order to eliminate the effects of damage to the gastrointestinal tract with the use of antiplatelet drugs, based on salicylic acid, using a natural dipeptide carnosine, a new compound was synthesized - salicyl-carnosine, which has an antiplatelet effect. A comparative study on carnosine, acetylsalicylic acid and salicyl-carnosine for the healing of ulcerative defect was carried out on the model of acetate gastric ulcer by Okabe. It was shown that salicyl-carnosine was more effective than carnosine both at the stage of ulcer formation (1-5 s) and at the stage of healing (5-10 s). Acetylsalicylic acid in the used model of gastric ulcer not only did not prevent the development of gastric ulcer, but also complicated the healing processes. The results indicate the possible prospects for the use of salicyl-carnosine as an antiplatelet drug in vascular pathologies (cardiac, Central nervous system, etc.), to avoid side effects associated with damage to the gastrointestinal tract, inherent in aspirin and other NSAIDs. Non-steroidal anti-inflammatory drugs.

• References total 16 ⇓ :: .
  1. Sergeev D. V., Tanashyan M. M., Piradov M. A. Antiagregantnaya terapiya pri ishemicheskom insul’te: problemy i perspektivy. RMZH Nevrologiya Psihiatriya. 2012, no.31, pp. 1536-1540.
  2. Domashenko M. A., Tanashyan M. M. Acetilsalicilovaya kislota v lechenii i profilaktike ishemicheskih narushenij mozgovogo krovoobrashcheniya. RMZH Nevrologiya Psihiatriya.2011, Vol.19, no 9, pp. 562-573.
  3. Frolov P. F., Gitik A. S., Normark P. R., Umans’ka S.B, Dikans’ka E.M., Markus I. M., Boguslavs’ka E.M., Sokolovs’ka N.I., Taratushkina K. K., Rozencvejg B. K., Vorobjov A. M., Ioselevich N. I. Eksperim. med. (ukr.). 1936, Vol. 2, pp. 65-78.
  4. Boldyrev A. A. Retrospectives and perspectives on the biological activity of histidine-containing dipeptides. Int. J. Biochem., 1990, 22, с. 129-132.
  5. Seiki M., Ueki S., Tanaka Y. et al. Studies on anti- ulcer effect of a new compound, zinc L- carnosine (Z- 103) // Nippon. Yakurigaku. Zasshi. 1990, Vol.95, № 5, P. 257-269.
  6. Trubicyna I. E., SHabanova M.E., CHikunova B.Z., SHavrackij V.H., Formazyuk V. B., Sergienko V. I., Stvolinskij S. L., Boldyrev A. A. Harakteristika protivoyazvennoj aktivnosti karnozina. Pat. fiziol. i ehksperim. terapiya. 1997, no.4, pp. 17-20.
  7. Ishikawa, M., Seiki, M., Ueki, S., Tanaka, Y., Soeda, M., Hori, Y., Tagashira, E. and Okabe, S.: Effect of a new compound, zinc L-carnosine (Z-103), on various gastric and duodenal lesions in rats. Japan. J. Pharmacol. 49 Supp. 190P (1989)
  8. Ito M, Tanaka Т., Suzuki Y. Effect of N-(3-aminopropionyl)-L-histidinato zinc (Z-103) on healing and hydrocortisone-induced relapse of acetic acid ulcers in rats with limited food-intake-time. Japan. J. Pharmacol, 1990, V.52, pp. 513-521.
  9. Matsukura, T., Takahashi, T., Nishimura, Y., Ohtani, T. Sawada, M., and Shibata, K. Characterization of crystalline L-carnosine An (II) complex (Z-103), a novel anti-gastric ulcer agent: tautomeric change of imidazole moiety upon complexation. Chem Pharm Bull. 1990;38:3140-3146.
  10. Cho С. М., Luk С. Т., Ogle С. W. The membrane-stabilizing action of zinc carnosine (Z-103) in stress-induced gastric ulceration in rats. Life Sci, 1991, V.49, pp. 189-194
  11. Takagi, K., Okabe, S. and Saziki, R.: A new method for the production of chronic gastric ulcer in rats and the effect of several drugs on its healing. Japan. J. Pharmacol. 19, 418-426 (1969)
  12. Okabe S., Pfeiffer C. Effects of propantheline bromide and milk plus cheese on healing of chronic gastric ulcers in rats// Am. j. Dig, Diseases. 1973, V. 18, P. 746-754,
  13. Kerola M, Vuolteenaho K, Kosonen O, Kankaanranta H, Sarna S, Moilanen E. Effects of nimesulide, acetylsalicylic acid, ibuprofen and nabumetone on cyclooxygenase-1- and cyclooxygenase-2-mediated prostanoid production in healthy volunteers ex vivo. Basic Clin Pharmacol Toxicol. 2009 Jan;104(1):17-21. doi: 10.1111/j.1742-7843.2008.00332
  14. Watari I., Oka S., Tanaka Sh., Aoyama T., Imagawa H., Shishido T., Yoshida Sh. and Chayama K. Effectiveness of polaprezinc for lowdose aspirin-induced small-bowel mucosal injuries as evaluated by capsule endoscopy: a pilot randomized controlled study. BMC Gastroenterology 2013 13:108. doi:10.1186/1471-230X-13-108
  15. Mahmood A, A J FitzGerald, T Marchbank, E Ntatsaki, D Murray, S Ghosh, R J Playford. Zinc carnosine, a health food supplement that stabilises small bowel integrity and stimulates gut repair processes. Gut 2007; 56:168-175. doi: 10.1136/gut.2006.099929
  16. Nikitenko N. Yu., Shavratsky V. Kh., Boldyrev A. A., et al. Effect of carnosine and its derivative on the ADP-induced aggregation of human trombocytes. Voprosy Meditsinskoy Khimii, 1995, V.41, no. 1, pp.562-573.

Full text is published :
Trubitsyna I. E., Stvolinsky S. L., Kulikova O. I., Fedorova T. N., Tarasova T. B., Efremov L. I., Mikhailova S. F., Varvanina G. G. Protective effect of the new compound — salicyl-carnosine — on the formation of chronic acetate gastric ulcer in rats. Experimental and Clinical Gastroenterology. 2019;163(3):58–64. (In Russ.) DOI: 10.31146/1682-8658-ecg-163-3-58-64
Read & Download full text

1. Republican Specialized Scientifi c and Practical Medical of Pediatrics, 100174 Tashkent, Uzbetkistan
2. Center of Advanced Technologies under the Ministry of Innovation Development of the Republic of Uzbekistan, 100174 Tashkent, Uzbetkistan

Keywords: Chronic enteral insuffi ency, oxidative phosphorylation, mytochondria, phytoecdysteroid, ecdysten

Abstract: Aim.To study the state of oxidative phosphorylation in a model of chronic enteral insufficiency in the growing rats and to assess the effectiveness of ecdystene in their correction. Materials and methods. Laboratory white mongrel rats were used in the experiments. The animals were divided into 3 groups. 1 group - healthy animals (control). Group 2 - animals on a diet poor in protein (chronic malnutrition), group 3 - animals that received as a corrective drug ecdysthene. Mitochondria were isolated from the liver of 40-day-old rats by differential centrifugation. The parameters of oxidative phosphorylation, respiration rate of isolated mitochondria in the metabolic state V4 and V3, as well as the values of respiratory control and ADP / O were determined. Results. Treatment of rats with protein deficiency for 10 days with the drug ecdystene resulted in a significant increase in the body weight of the rats - an average of 45.5% - and by the 10th day of treatment this value was 71% of the values in the control group (P <0.01). In the group of animals that were on a diet poor in proteins, the oxidative phosphorylation parameters were significantly reduced. The rate of oxygen consumption by the mitochondrial suspension in the functional state of V3 and V4 in sick animals was almost half that in control animals. Respiratory control, in the group of sick animals was reduced by 20%. The ratio of ADP / O was also reduced and was 2.5 vs 2.8 in the control group. When using a corrective ecdystene preparation as a quality, the V3 state was 93.72, V4 was 15.62, and Vdnf was 109.34 ng at O / min / mg protein (P <0.001). The value of the respiratory control was also close to the control and was 6, and the ratio of ADP / O even slightly exceeded the control value and was 3.03 (P <0.05). Сonclusion. We detected a pronounced disconnection of the respiratory chain in the mitochondrial suspension when the animals were kept on a diet poor in proteins and also had a bright corrective effect in the ecdystene. The therapeutic effect of ecdysten revealed its pronounced ability to correct manifestations of chronic enteric insufficiency in growing rats.

• References total 18 ⇓ :: .
  1. Popova T. S., SHestopalov A.E., Tamazashvili T.SH., Lejderman I. N. Nutritivnaya podderzhka bol’nyh v kriticheskih sostoyaniyah [Nutritional support for critically ill patients]. M. OOO «Izdat.dom «M-Vesti», 2002.-320 p., pic.36.
  2. Chubarova Ai, Mukhina Y. G., Slabuka N. V., Lysikov Yu. A. Morphological indicators of different intestinal departments in children of the first year of life in postrescent syndrome. Experimental and Clinical Gastroenterology Journal. 2010, no.1, pp. 64-70/
  3. Alyamovskaya G. A., Zolkina I. V., Keshishyan E. S. Vtorichnaya karnitinovaya nedostatochnost’ u nedonoshennyh detej s massoj tela pri rozhdenii menee 1500 g. v patogeneze ehnergeticheskogo deficita na pervom-vtorom godu zhizni i vozmozhnosti ee korrekcii. [Secondary carnitine deficiency in premature babies with birth weight less than 1500, in the pathogenesis of energy deficit in the first or second year of life and the possibility of its correction]. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2012;4(2):126-131.
  4. Bel’skih EH. S. Sovremennye predstavleniya o patogeneze i podhodah k korrekcii mitohondrial’noj disfunkcii. EH. S. Bel’skih, V. I. Zvyagina, O. M. Uryas’ev. Nauka molodyh - EruditioJuvenium. 2016, no. 1, pp. 104-112.
  5. YU. A. Vasyuk, K. G. Kulikov, O. N. Kudryakov et al. Vtorichnaya mitohondrial’naya disfunkciya pri ostrom koronarnom sindrome Racional’naya farmakoterapiya v kardiologii. 2007, no. 1, pp. 41-47.
  6. Ziganshina A. A. Gastrointestinal’nye proyavleniya mitohondrial’noj disfunkcii. Rossijskij vestnik perinatologii i pediatrii. 2016, vol. 61, no. 6, pp. 38-42.
  7. Globa O. V., ZHurkova N. V., Kondakova O. B., et al. Klinicheskij polimorfizm mitohondrial’noj disfunkcii u detej [Clinical polymorphism of mitochondrial dysfunction in children]. Sovremennye problemy nauki i obrazovaniya [Modern problems of science and education]. 2008, no. 4, pp. 52-53.
  8. Leont’eva I. V., Alimina E. G., Zolkina I. A. et al. The clinical significance of carnitine metabolism in children with cardiomyopathy. Praktika pediatra [Pediatrician practice], 2012, vol. 4, № 2, pp. 74-79.
  9. Natalia Nieto, Mar´ia Dolores Mesa, Jos´eMari´a Lo´ pez-Pedrosa, M. Isabel Torres, AntonioRi´os, Mari´a Dolores sua´ rez, and A´ ngel Gil. Contribution of Polyunsaturated Fatty Acids to Intestinal Repair in Protein-Energy Malnutrition. Digestive Diseases and Sciences, Vol. 52, No. 6 (June 2007), pp. 1485-1496 (C _ 2007) DOI: 10.1007/s10620-007-8100-9
  10. Giguere-Rich C, Mathew A, Reid E, Autore K, Guill MF. JPEN J Parenter Enteral Nutr. 2018 Jan;42(1):225-230. doi: 10.1002/jpen.1011. Epub 2017 Dec 13. Single-Center Experience with the Use of Teduglutide in Adult Patients with Short Bowel Syndrome.
  11. JPEN J Parenter Enteral Nutr. 2018 Apr 27. Pediatric Intestinal Failure: The Key Outcomes for the First 100 Patients Treated in a National Tertiary Referral Center During 1984-2017.
  12. Merras-Salmio L, Mutanen A, Ylinen E, Rintala R, Koivusalo A, Pakarinen MP. Use of an In-line Digestive Cartridge With Enteral Nutrition Improves the Weight Trajectory of 2 Children With Cystic Fibrosis Complicated by Another Medical Diagnosis. NutrClinPract. 2018 Apr;33(2):286-294. doi: 10.1002/ncp.10080.
  13. Syrov V. N., Hushbaktova Z. A., Komarin A. S., Abidov A. B., Pechenicyna T. V., Ariphodzhaeva F. A. EHksperimental’no-klinicheskaya ocenka ehffektivnosti primeneniya ehkdistena pri lechenii gepatita. EHkcpepimental’naya i klinicheckaya fapmakologiya 2004, Vol. 67, no. 5, pp. 56-59.
  14. Schnelder W.C., Hogeboom G. H. Ann. Rev. Biochem., 1956. 25. 201
  15. Praktikum po biohimii, 1989
  16. Leninger A. Fundamentals of biochemistry. Volume 3. Trans. from English Moscow, Mir, 1986, 368 p.
  17. Francoise Briet, Clare Twomey, and Khursheed N Jeejeebhoy. Effect of malnutrition and short-term refeeding on peripheral blood mononuclear cell mitochondrial complex I activity in humans. Am J ClinNutr. 1-3/ 2003;77:1304-11. Printed in USA. © 2003 American Society for Clinical Nutrition
  18. Bonnemains C, Feillet F. Diagnosis and management of hyperammonemia. ArchPediatr. 2009 Jun;16(6):634-6.

Full text is published :
Kamilova А. Т., Dustmuhamedova D. H., Levickaya Yu. V. Disorders of oxidative phosphorylationin the model of chronic enteral insufficiency and their correction. Experimental and Clinical Gastroenterology. 2019;163(3): 65–69. (In Russ.) DOI: 10.31146/1682-8658-ecg-163-3-65-69
Read & Download full text

1. Federal State Budgetary Educational Institution of Higher Education “Rostov State Medical University” of the Ministry of Healthcare of the Russian Federation, 344022, Rostov-on-Don, Russia
2. Сlinical diagnostic center “Zdorovie”, 344011, Rostov-on-Don, Russia

Keywords: Chronic enteral insuffi ency, oxidative phosphorylation, mytochondria, phytoecdysteroid, ecdysten

Abstract: Radiofrequency ablation can achieve a significant reduction of simple liver cysts. The aim of the study was to investigate the effects of RFA in various regimes on the wall of the liver cyst and adjacent tissue, and to define optimal exposure parameters. Materials and methods. An experimental study was performed by constructing of imitational models of a simple liver cyst (group № 1), a biliary cyst (group № 2), and a cyst with high electrical conductivity content (10% NaCl solution) -group № 3. The models were exposed to RFA in the range of temperatures from 50 to 92 °C with duration from 1 to 5 minutes. Then, the postablation changes of the preparations were assessed using histological examination. Results. In all groups, when heated, there was a lag of the temperature of the cystic medium compared with the temperature of the electrode. For models of group № 1, № 2, and № 3, the difference was 19.6 °C, 8.75 °C, and 3.8 °C, respectively. Coagulation necrosis was found in all preparations and was most pronounced in the surface layers of the tissue contacted with the heated medium. The absence of destruction of the adjacent liver tissue in group № 1 was found for RFA in regimes using 61-63 °C for 2 minutes; in group 2 - using 65-75 °C for 3 minutes; in group 3 - using 85 °C (for 2 minutes) or 53-55 °C (for 5 minutes). Conclusion. The destruction of all epithelial cells is achievable with RFA; however, the thermal range between total ablation and the thermal injury of adjacent healthy tissue is narrow. The introduction of 10% NaCl solution can increase the area of necrosis and makes possibility to control the temperature of the cyst. Achieving mild ablation with shallow penetration of necrosis is influenced by the volume and electrical conductivity of the cystic content, adequate control of the temperature in the cystic cavity, and dosed use of RFA power and exposure time.

• References total 23 ⇓ :: .
  1. Qi, X., Shao, H., Zhang, J. et al. Radiopharmaceutical study on Iodine-131-labelled hypericin in a canine model of hepatic RFA-induced coagulative necrosis. Radiol med (2015) 120: 213. https://doi.org/10.1007/s11547-014-0433-9
  2. Kim PN, Lee Y, Won HJ, Shin YM. Radiofrequency ablation of hepatic cysts: evaluation of therapeutic efficacy. J Vasc Interv Radiol 2014 Jan;25(1):92-6. doi: 10.1016/j.jvir.2013.09.020.
  3. Rhim H, Kim YS, Heo JN, et аl. Radiofrequency thermal ablation of hepatic cyst. J Vasc Interv Radiol. 2004 Jan;15(1 Pt 1):95-6
  4. Cherkasov M. F., Aboyan I. A., Pavlov S. V. et al. Primenenie modificirovannogo sposoba radiochastotnoj ablyacii v lechenii prostyh neparazitarnyh kist pecheni. 5 S’ezd hirurgov Yuga Rossii s mezhdunarodnym uchastiem, tezisy: 18-19 maya 2017 g. FGBOU VO RostGMU Minzdrava Rossii. Rostov n/D., Izd-vo RostGMU Publ., 2017, P. 469.
  5. Kim SH, Lim HK, Choi D, et аl. Changes in bile ducts after radiofrequency ablation of hepatocellular carcinoma: frequency and clinical significance. American Journal of Roentgenology. 2004;183: 1611-1617. 10.2214/ajr.183.6.01831611
  6. Park JS, Jeong S, Kim JM, et al. Development of Swine Benign Biliary Stricture Model Using Endoscopic Biliary RadiofrequencyAblation. J Korean Med Sci. 2016 Sep;31(9):1438-1444 https://doi.org/10.3346/jkms.2016.31.9.1438.
  7. Larssen T.B., Rorvik J., Horn A. et al. Biochemical and cytologic analysis of cystic contents in benign non-parasitic symptomatic hepatic cysts before and after ethanol sclerotherapy. Acta Radiol. 2004, Vol. 45, N5, P. 504-509
  8. Kochieva M. P., Bagmet N. N., Abdullayev A. G., Skipenko O. G. Treatment of biliary cysts of the liver and polycystic liver disease: a surgical view. RJGHC. 2010, Vol. 20, No. 1, pp. 30-37.
  9. Inayoshi A., Sawada T., Azuma K., Yagi Y. Three cases of nonparasitic liver cyst treated by intracystic instillation of acetic acid under ultrasonic guidance. Nihon Shokakibyo Gakkai Zasshi. 1997, Vol. 94, N9, P. 627-631. Available at: https://www.ncbi.nlm.nih.gov/pubmed/9311243
  10. Lee S, Seo DW, Paik WH, et al. Ethanol lavage of huge hepatic cysts by using EUS guidance and percutaneous approach. Gastrointest Endosc. 2014 Dec; 80(6):1014-21. doi: 10.1016/j.gie.2014.03.037. Epub 2014 Jun 2.
  11. Plard L., Guedin P., Le Pennec V., Chiche L. Hepatic cysts: diagnosis and management. J. Chir. (Paris). 2008, Vol. 145, N3, P. 217-225.
  12. Rukovodstvo po hirurgii pecheni i zhelchevyvodyashchih putej. Pod red. A. E. Borisova. Vol I. SPb, «Predpriyatie EHFA», 2002, 250 p.
  13. Song H, Rhim H, Choi JB, et al. Radiofrequency thermal ablation of benign cystic lesion: an experimental pilot study in a porcine gallbladder model. J Korean Radiol Soc 2001; 44:571-576. Available at: https://inis.iaea.org/search/search.aspx?orig_q=RN:32058625
  14. Bean W.J., Rodan B. A. Hepatic cysts: treatment with alcohol. AJR Am. J. Roentgenol. 1985, Vol. 144, P. 237-241. doi: 10.2214/ajr.144.2.237
  15. Okano A., Hajiro K, Takakuwa H, Nishio A. Alcohol sclerotherapy of hepatic cysts: its effect in relation to ethanol concentration. Hepatol. Res. 2000, Vol. 17, N3, P. 179-184. doi: https://doi.org/10.1016/S1386-6346(99)00067-4
  16. Dolgushin B. I., Kosyrev V. Yu. Radiochastotnaya termoablaciya opuholej. Moscow, Prakticheskaya medicina Publ., 2015. pp. 44-45.
  17. Coleman CC, Vennes JA, Posalaky IP, Amplatz K. Thermal ablation of the gallbladder. Radiology. 1991 Aug; 180(2):363-6. doi: 10.1148/radiology.180.2.2068297
  18. Friedman M, Mikityansky I, Kam A et al. (2004) Radiofrequency ablation of cancer. Cardiovasc Intervent Radiol 27:427-434. doi: https://doi.org/10.1007/s00270-004-0062-0
  19. Lee JM, Han JK, Kim SH, et al. Comparison of wet radiofrequency ablation with dry radiofrequency ablation and radiofrequency ablation using hypertonic saline preinjection: ex vivo bovine liver. Korean J Radiol. 2004;5(4):258-65.
  20. Lee JM, Han JK, Kim SH, et al. Comparison of wet radiofrequency ablation with dry radiofrequency ablation and radiofrequency ablation using hypertonic saline preinjection: ex vivo bovine liver. Korean J Radiol. 2004;5(4):258-65. doi: https://doi.org/10.3348/kjr.2004.5.4.258
  21. Lee JM, Kim YK, Lee YH, et al. Percutaneous radiofrequency thermal ablation with hypertonic saline injection: in vivo study in a rabbit liver model. Korean J Radiol. 2003;4(1):27-34.
  22. Lu DS, Raman SS, Vodopich DJ, et al. Effect of vessel size on creation of hepatic radiofrequency lesions in pigs: assessment of the “heat sink” effect. American Journal of Roentgenology. 2002;178: 47-51. doi: 10.2214/ajr.178.1.1780047
  23. Aagaard BD, Wetter LA, Montgomery CK, Gordon RL. Heat ablation of the normal gallbladder in pigs. J Vasc Interv Radiol. 1994;5:331-9

Full text is published :
Cherkasov M. F., Aboyan I. A., Aboyan M. E., Roshak B. V., Lemeshko S. I., Malikov L. L., Khanamirova L. Z., Buharbaev R. M., Melikova S. G. Reducing the size of the experimental liver brush using radiofrequency ablation. Experimental and Clinical Gastroenterology. 2019;163(3): 70–76. (In Russ.) DOI: 10.31146/1682-8658-ecg-163-3-70-76
Read & Download full text

1. Irkutsk Scientifi c Center of the Siberian Branch of the Russian Academy of Sciences (664033, Irkutsk, Russia)
2. Irkutsk Scientifi c Center for Surgery and Traumatology (664003, Irkutsk, Russia)
3. Irkutsk Regional Clinical Hospital (664049, Irkutsk, Russia)

Keywords: ---

Abstract: ------.

• References total 8 ⇓ :: .
  1. Iskra A. I., Lepehova S. A. Perspektiva ispol’zovanija biotehnologij dlja korrekcii pechenochnoj nedostatochnosti (obzor literatury) [The prospect of using biotechnology for the correction of liver failure (literature review)]. Bjulleten’ Vostochno-Sibirskogo nauchnogo centra Sibirskogo otdelenija Rossijskoj akademii medicinskih nauk - [Bulletin of the East-Siberian Scientific Center of the Siberian Branch of the Russian Academy of Medical Sciences], 2014, no.1 (95), pp. 112-119.
  2. Razumova M. S., Litvinova E. S., Bystrova N. A., Chueva T. V. Metabolicheskaja aktivnost’ kul’tural’noj zhidkosti ksenogennyh, allogennyh gepatocitov i fibroblastov v uslovijah jeksperimental’nogo ostrogo tetrahlormetanovogo porazhenija pecheni [Metabolic activity of culture fluid of xenogenic, allogeneic hepatocytes and fibroblasts under conditions of experimental acute tetrachloromethane liver damage]. Kurskij nauchno-prakticheskij vestnik Chelovek i ego zdorov’e - [Kursk Scientific and Practical Gazette Man and his health], 2016, no. 2, pp. 74-80.
  3. Ramachandran A. Jaeschke H. Mechanisms of acetaminophen hepatotoxicity and their translation to the human pathophysiology. J. Clin. Transl. Res. 2017 Feb;3.(Suppl 1). pp. 157-169. doi: 10.18053/jctres.03.2017S1.002.
  4. Tang D. Wang F. Tang J. et al. Dicranostiga leptopodu (Maxim.) Fedde extracts attenuated CCl4-induced acute liver damage in mice through increasing anti-oxidative enzyme activity to improve mitochondrial function. Biomed Pharmacother. 2017 Jan;85. pp.763-771. doi: 10.1016/j.biopha.2016.11.097. Epub 2016 Dec 4.
  5. Lepehova S. A. Sanogenez pechenochnoj nedostatochnosti pod vlijaniem ksenotransplantacii kletok pecheni i selezenki (jeksperimental’noe issledovanie). Avtoreferat Diss. dokt. biol. nauk [Sanogenesis of liver failure under the influence of xenotransplantation of liver and spleen cells (experimental study). Abstract Dr. biol. sci. diss.]. Irkutsk, 2010, 47 p.
  6. Avtandilov G. G. Morfometrija v patologii. [Morphometry in pathology]. Moscow, Medicine, 1973. 248 p.
  7. Fisher A. Fiziologija i jeksperimental’naja patologija pecheni [Physiology and experimental pathology of the liver]. Budapest, 1961. 230 p.
  8. Sprejs I. F., Alferova M. A., Mihalevich I. M., Rozhkova N. Ju. Osnovy prikladnoj statistiki (ispol’zovanie Excel i Statistica v medicinskih issledovanijah): uchebnoe posobie [Fundamentals of applied statistics (use of Excel and Statistica in medical research): study guide.]. Irkutsk, RIO GIUV, 2006, 71 p.

Full text is published :
Lepekhova S. A., Goldberg O. A., Prokop’ev M. V., Kurgansky I. S., Kireeva V. V., Inozemcev P. O., Apartsin K. A. Effect of toxic liver damage on structural changes in mitochondria and intracellular organelles. Experimental and Clinical Gastroenterology. 2019;163(3): 77–80. (In Russ.) DOI: 10.31146/1682- 8658-ecg-163-3-77-80
Read & Download full text

1. Saratov state medical university of V. I. Razumovsky of the Russian Ministry of Health, Saratov, Russia
2. Branch of private institution of the educational organization of the higher education “The medical university “Reaviz”, Saratov, Russia

Keywords: sharp cholecystitis. mechanical jaundice, system infl ammatory answer (SIRS)

Abstract: The modern literary review the devoted question of sharp cholecystitis and mechanical jaundice is presented in article, it is established that now weight of a condition of the patient with sharp cholecystitis and mechanical jaundice is still estimated on kliniko-biochemical weight of an ikterus and the progressing liver failure. Other syndromes are considered insufficiently. It is especially important to reflect a syndrome of the system inflammatory answer (SIRS) which reflects weight of the developing inflammatory process in a biliarny system.

• References total 62 ⇓ :: .
  1. Kasum’yan S. A. Ispol’zovanie laparoskopii pri ostrom holecistite u bol’nyh s vysokim operacionnym riskom [Use of laparoscopy at sharp cholecystitis at patients with high operational risk]. Endoscopic surgery. 2005; 1: 68-69.
  2. Stolin A.V., Prudkov M. I. Vozmozhnosti hirurgicheskogo lecheniya bol’nyh ostrym kal’kuleznym holecistitom, oslozhnennym mekhanicheskoj zheltuhoj [Possibilities of surgical treatment of patients with the sharp kalkulezny cholecystitis complicated by mechanical jaundice]. Endoscopic surgery. 2007; 1: 54.
  3. Belyaev L. B. Prognozirovanie i profilaktika posleoperacionnyh oslozhnenij u bol’nyh zhelchnokamennoj bolezn’yu i mekhanicheskoj zheltuhoj neopuholevogo proiskhozhdeniya: kliniko-ehksperim. Issledovanie [Forecasting and prevention of postoperative complications at patients with cholelithiasis and mechanical jaundice of not tumoral origin: kliniko-pilot study]: Abstract… theses of the candidate of mediitsinsky sciences. - L., 1991, 35 p.
  4. Bjornsson E., Gustafsson J., Borkman J. et al. Fate of patients with obstructive jaundice. Jornal of hospital Medicine. 2008, Vol. 3 (1,2), P. 117-123.
  5. Starosec V. N., KHilco S.S., Vlakhov A. K. et al. Modern tendencies in surgical treatment of patients with obturation jaundice complicated by hepatic insufficienc. Klin. Khir. 2009, Vol. 4, P. 117-123.
  6. Zarkua N. EH. Navigacionnye tekhnologii lecheniya bol’nyh ostrym holecistitom i vysokim indeksom komorbidnosti [Navigation technologies of treatment of patients with sharp cholecystitis and high index of a komorbidnost]. The I congress of the FEFD together with the scientific and practical conference devoted to the 145 anniversary of naval clinical hospital of the Pacific fleet - Vladivostok, on September 13-15, 2017. Theses: 140-141.
  7. Uhanov A. P., CHarchyan G.L., Novozhilov E. V. Rezul’taty ispol’zovaniya ehndovideohirurgicheskoj i tradicionnoj holecistehktomii u bol’nyh ostrym destruktivnym holecistitom v razlichnyh vozrastnyh gruppah [Results of use of an endovideo surgical and traditional holetsistektomiya at patients with sharp destructive cholecystitis in various age groups]. Almanac of Institute of surgery of A. V. Vishnevsky the XVIII Congress of Society of endoscopic surgeons of Russia Moscow, on February 17-19, 2015. Theses 170.
  8. Pokrovskij E.ZH., Stankevich A. M., Balagurov B. A. Stentirovanie vnepechenochnyh zhelchnyh protokov u bol’nyh mekhanicheskoj zheltuhoj s tyazheloj soputstvuyushchej patologiej [Stenting of extra hepatic bilious channels at patients with mechanical jaundice with the heavy accompanying pathology]. Almanac of Institute of surgery of A. V. Vishnevsky № 2 of 2017. The first Congress of surgeons of Central Federal District of the Russian Federation Ryazan, on September 27-29, 2017: 92-93.
  9. Hil’ko S.S., Starosek V. N., Vlahov A. K. Ocenka ehffektivnosti metodov korrekcii narushenij funkcional’nogo sostoyaniya pecheni pri holestaze mekhanicheskoj prirody [Assessment of efficiency of methods of correction of violations of a functional condition of a liver at a holestaza of the mechanical nature]. Клiн xipypгiя. 2005;10: 16-18.
  10. Starosek V. N., Hil’ko S.S., Vlahov A. K. Sovremennye tendencii hirurgicheskogo lecheniya bol’nyh s obturacionnoj zheltuhoj, oslozhnennoj pechenochnoj nedostatochnost’yu [Current trends of surgical treatment of patients with the obturatsionny jaundice complicated by a liver failure]. Clinical Surgery. 2009; 4: 15-18.
  11. Pikovskij D. L. Idei i vzglyady S. P. Idei i vzglyady S. P. Fedorova kak osnova stanovleniya i razrabotki teorii zhelchnoj gipertenzii [Ideas and S. P. Fedorov’s views as basis of formation and development of the theory of bilious hypertensia]. Bilious hypertensia and surgery of bilious ways. Volgograd, 1980: 4-13.
  12. Gal’perin EH.I., Momunova O. N. Klassifikaciya tyazhesti mekhanicheskoj zheltuhi [Classification of weight of mechanical jaundice]. Surgery. The magazine of N. I. Pirogov. 2014; 1: 5-9.
  13. Нecht Y. Biliary scintigraphy.Application to the study of chronic cholestasis. Presse Medic. 1993, Vol. 22, № 28.3, P. 1307-1312.
  14. Reichen I. Pharmacologic treatment of cholesnasis. Semin. Liver Dis. 1993, Vol. 13, № 3, P. 302-315.
  15. Hryachkov V. V. Osobennosti lecheniya ostrogo holecistita u lic pozhilogo i starcheskogo vozrasta [Features of treatment of sharp cholecystitis at persons of advanced and senile age]. Materials of a plenum of the problem commission “Urgent surgery”. Moscow - Pyatigorsk, 2005: 68-70
  16. Girard R., Morin M. Open cholecystectomy: its mortality and morbidity as a reference standard.. Can. J. Surg. 1999, Vol. 36, № 1, P. 75-80.
  17. TG13 miscellaneous etiology of cholangitis and cholecystitis. Ryota Higuchi, Tadahiro Takada, Steven M. Strasberg, Henry A. Pitt, Dirk J. Gouma, O. James Garden, Markus W. Buchler, John A. Windsor, Toshihiko Mayumi, Masahiro Yoshida, Fumihiko Miura, Yasutoshi Kimura, Kohji Okamoto, Toshifumi Gabata, Jiro Hata, Harumi Gomi, Avinash N. Supe, Palepu Jagannath, Harijt Singh, Myung-Hwan Kim, Serafin C. Hilvano, Chen-Guo Ker, Sun-Whe Kim. J Hepatobiliary Pancreat Sci (2013) 20, P. 97-105.
  18. Gallstone disease: diagnosis and management. NICE Clinical guideline [CG188] 2014. https://www.nice.org.uk/ guidance/cg188/ chapter/1- recommendations/
  19. Ansaloni L, Pisano M, Coccolini F. et al. 2016 WSES guidelines on acute calculous cholecystitis. World J Emerg. Surg. 2016, P. 11:25. DOI 10.1186/s13017-016-0082-5.
  20. Williams E., Beckingham I., Sayed G. et al. Updated guideline on the management of common bile duct stones (CBDS). Gut. 2017, № 66 (5), P. 765-782.
  21. Korolev, B.A., Pikovskij, D.L. EHkstrennaya hirurgiya zhelchnyh putej [Emergency surgery of bilious ways]. Moscow, «Medicine» of 1990, 239 p.
  22. Gal’perin EH.I. Rukovodstvo po hirurgii zhelchnyh putej [Guide to surgery of bilious ways]. M.: Vidar-M, 2009, 568 p.
  23. Gal’perin EH.I., Tatishvili T. T., Ahaladze G. G. Novye kriterii ocenki tyazhesti mekhanicheskoj zheltuhi i gnojnogo holangita [New criteria for evaluation of weight of mechanical jaundice and purulent holangit]. Mechanical jaundice: Tez. interregion. surgeons. M, 1993: 19-20.
  24. Belyaev A. N., Belyaev S. A., Kostin S. V., Hvostunov S. I., Elistratov YU.V., Cerkovnov S. S. Intensivnaya terapiya pechenochnoj nedostatochnosti pri mekhanicheskoj zheltuhe [Intensive therapy of a liver failure at mechanical jaundice]. Medical almanac. 2012; 2: 167-170.
  25. Vishnevskij V. A., SHadin I.M., Bruslik V. G. Profilaktika i lechenie pechenochnoj nedostatochnosti u bol’nyh s mekhanicheskoj zheltuhoj [Prevention and treatment of a liver failure at patients with mechanical jaundice]. The first Moscow international congress of surgeons. М., 1995: 250-251.
  26. Beners U. Tayroursodeoxycholic acid stimulated hepatocellular exocy-tosis and mobilized extracellular Ca++ mechanisms defective in cholestasis. J. clin. inv. 1993, № 6, P. 2984-2993.
  27. Drozhzhilov M. A. Rannyaya diagnostika ostroj pechenochnoj nedostatochnosti u bol’nyh s mekhanicheskoj zheltuhoj [Early diagnosis of an acute liver failure at patients with mechanical jaundice]. Diss. of the candidate of medical sciences. Chelyabinsk, 1995: 10-17.
  28. Grigorescu M. The biochemical profile of the cholestatic syndrome. Med. Interna. 1992. Vol. 44, № 2, P. 34-40.
  29. Radominska A. Bile asid metabolism and the pathophisiology of cholestasis. Semular Liver Dis. 1993, Vol. 13, № 3, P. 219-234.
  30. Zhan S. L. Chemical study on the immune function of patient with obstructive jaundise. Chung Hua Wai Ko Tsa Chih. 1993, Vol. 31, № 8,P. 480-483.
  31. Belyaev A. N., Kozlov S. A., Belyaev S. A. Funkcional’nye i morfologicheskie narusheniya pecheni pri ostrom obturacionnom holestaze i ih korrekciya (ehksperimental’noe issledovanie) [Functional and morphological violations of a liver at a sharp obturatsionny holestaz and their correction (pilot study)]. Annals of surgical hepatology. 2014; 4 (19): 64-70.
  32. Val’kov K.S., Gagua A.K, Akajzin EH.S. Dinamika pokazatelej letuchih zhirnyh kislot, citrullina i malonovogodial’degida v kompleksnoj ocenke pechyonochnoj nedostatochnosti u bol’nyh mekhanicheskoj zheltuhoj s gnojnym holangitom [Dynamics of indicators of flying fatty acids, a tsitrullina and a malonovogodialdegida in complex assessment of a liver failure at patients with mechanical jaundice with a purulent holangit]. Bulletin of the Ivanovo medical academy. 2016; 2 (21): 41-45.
  33. Saurez-Munoz M. A. Risk factors and classifi cations on hilar cholangiocarcinoma. World J. Gastointest. Oncol. 2013, № 7, P. 132-138.
  34. Lu Y., Zhang B. Y., Zhao C., Jin X. Effect of obstructive jaundice on hemodynamics in the liver and its clinical signifi cance. Hepatobiliary Pancreat. Dis. Int. 2009, № 8 (5), pp. 494-497.
  35. Ioffe I. V., Poteryahin V. P. Dinamika izmenenij biohimicheskih pokazatelej krovi u bol’nyh pri obturacionnoj zheltuhe, obuslovlennoj holedoholitiazom, pod vliyaniem plazmafereza [Dynamics of changes of biochemical indicators of blood at patients at the obturatsionny jaundice caused holedokholitiazy under the influence of a plasma exchange]. Clinical Surgery. 2010; 4: 19-20.
  36. Lu Y., Cheng X. Z. Xiong Two stage vs single-stage management for concomitant gallstones and common bile duct stones. World J. Gastroenterol. 2012, Vol. 18, № 24, P. 3156-3166.
  37. Bolevich S. B., Stupin V. A., Gahramanov T. V. Osobennosti techeniya svobodno radikal’nyh processov u bol’nyh s mekhanicheskoj zheltuhoj i metody ih korrekcii [Features of a course of freely radical processes at patients with mechanical jaundice and methods of their correction]. Surgery. 2010; 7: 65-70.
  38. Nazirboev K. R., Kurbonov K. M. Znachenie pokazatelej svobodnoradikal’nyh processov v ocenke tyazhesti mekhanicheskoj zheltuhi dobrokachestvennogo geneza [Value of indicators of free radical processes in assessment of weight of mechanical jaundice of good-quality genesis]. Almanac of Institute of surgery of A. V. Vishnevsky No. 1 of 2017. Theses the national surgical congress together with the XX anniversary congress of ROEH on April 4-7, 2017, Moscow: 1285-1286.
  39. Vlasov A. P., Zajcev P. P., Kurochka, YU.G. Korrekciya rasstrojstv gomeostaza pri mekhanicheskoj zheltuhe [Correction of frustration of a homeostasis at mechanical jaundice]. Almanac of Institute of surgery of A. V. Vishnevsky № 1 of 2018. Theses of the All-Russian surgical forum-2018 with the international participation there is M., on April 3-6, 2018: 102.
  40. Gal’perin EH.I. Mekhanicheskaya zheltuha: sostoyanie «mnimoj stabil’nosti», posledstviya «vtorogo udara», principy lecheniya [Mechanical jaundice: condition of “imaginary stability”, consequences of “second blow”, principles of treatment]. Annals of surgical hepatology. 2011; 3 (16): 16-25.
  41. Nakeeb A., Pitt H. A. Pathophysiology of biliary tract obstruction. Surg. Liver. Biliar. Tract Pancr. - 4thed. 2007, P. 79-86.
  42. Savenkov M. S., Petrova O. V., Bisalieva R. A., Nikulina D. M. Kompleksnaya laboratornaya ocenka vyrazhennosti vospalitel’nyh izmenenij pri obstruktivnom holecistite [Complex laboratory assessment of expressiveness of inflammatory changes at obstructive cholecystitis]. Bulletin of the Volgograd center Russian Academy of Medical Science and administration of the Volgograd region. 2006; 2: 51.
  43. Balalykin A. S., Mucurov H. S., Savin V.YU. EHndoskopicheskaya hirurgiya oslozhnennoj obstrukcij zhelchevyvodyashchej sistemy [Endoscopic surgery of the bile-excreting system complicated obstructions]. Almanac of Institute of surgery of A. V. Vishnevsky the XVIII Congress of Society of endoscopic surgeons of Russia, Moscow, on February 17-19, 2015. Theses 286.
  44. Balalykin A. S., Barbado I.YU., Mamedova P. A. K voprosu o nestandartnyh situaciyah v ehndoskopicheskoj chrespapillyarnoj hirurgii (EHCHPH) [To a question of unusual situations in endoscopic chrespapillyarny surgery (EChPH)]. Almanac of Institute of surgery of A. V. Vishnevsky No. 1 of 2017. Theses the National surgical congress together with the XX anniversary congress of ROEH on April 4-7, 2017, Moscow: 122-121.
  45. Korolev M. P., Fedotov L. E., Avanesyan R. G. Holedoholitiaz v nestandartnyh situaciyah. Sovremennye metody kombinirovannogo maloinvazivnogo lecheniya [Holedokholitiaz in unusual situations. Modern methods of the combined low-invasive treatment]. The almanac of Institute of surgery of A. V. Vishnevsky the XVIII Congress of Society of endoscopic surgeons of Russia - Moscow, on February 17-19, 2015. Theses 389.
  46. Barbado-Mamedova P.A., Mucurov H. S., Gvozdik V. V. Sindrom Mirizzi kak problema vnutriprosvetnoj ehndoskopicheskoj chrespapillyarnoj hirurgii [Syndrome of Mirizzi as problem of vnutriprosvetny endoscopic chrespapillyarny surgery]. Almanac of Institute of surgery of A. V. Vishnevsky № 1 of 2017. Theses the National surgical congress together with the XX anniversary congress of ROEH on April 4-7, 2017, - Moscow: 120-121.
  47. Dibirov M. D., Domarev L. V., Vasil’eva M. A. Profilaktika oslozhnenij miniinvazivnyh antegradnyh, retrogradnyh ehndoskopicheskih vmeshatel’stv pri mekhanicheskoj zheltuhe [Prevention of complications of miniinvasive antegradny, retrograde endoscopic interventions at mechanical jaundice]. Almanac of Institute of surgery of A. V. Vishnevsky the XVIII Congress of Society of endoscopic surgeons of Russia Moscow, on February 17-19, 2015. Theses 86.
  48. Dibirov M. D., EHl’derhanov M.M., Kosachenko M. V. Miniinvazivnye metody lecheniya mekhanicheskoj zheltuhi u lic s vysokim riskom [Miniinvasive methods of treatment of mechanical jaundice at persons with high risk]. Almanac of Institute of surgery of A. V. Vishnevsky No. 2 of 2017. The first Congress of surgeons of Central Federal District of the Russian Federation Ryazan, on September 27-29, 2017: 550.
  49. Mansurov U. U., Nazirboev K. R. Holecistostomiya u lic pozhilogo i starcheskogo vozrasta [Holetsistostomiya at persons of advanced and senile age]. Almanac of Institute of surgery of A. V. Vishnevsky No. 1 of 2017. Theses the national surgical congress together with the XX anniversary congress of ROEH on April 4-7, 2017, Moscow: 89.
  50. Mansurov U. U., Sarmisokov U. I. Holecistehktomiya iz mini-dostupa u bol’nyh ostrym holecistitom, oslozhnennym mekhanicheskoj zheltuhoj [Holetsistektomiya from mini-access at patients with the sharp cholecystitis complicated by mechanical jaundice]. Almanac of Institute of surgery of A. V. Vishnevsky No. 1 of 2017. Theses the national surgical congress together with the XX anniversary congress of ROEH on April 4-7, 2017, Moscow: 100.
  51. Mansurov U. H., Sarmisokov U. I., Muhammadiev D. I. Taktika hirurgicheskogo lecheniya pri oslozhnennyh formah zhelchnokamennoj bolezni [Tactics of surgical treatment at the complicated cholelithiasis forms]. Almakh Instituta of surgery of A. V. Vishnevsky No. 1 2017. Theses the national surgical congress together with the XX anniversary congress of ROEH on April 4-7, 2017, Moscow: 101.
  52. Abdullaev, EH.G., Babyshin, V.V., Gusev, A. V. Holecistehktomiya iz minidostupa u bol’nyh s soputstvuyushchimi zabolevaniyami [Holetsistektomiya from miniaccess at patients with associated diseases]. Almakh of institute of surgery of A. V. Vishnevsky the XVIII Congress of society endoscope. хирур. Russia Moscow, on February 17-19, 2015. Theses 78.
  53. Prudkov M. I. EHkspress-diagnostika gnojno-destruktivnyh form ostrogo kal’kuleznogo holecistita [Express diagnostics it is purulent - destructive forms of sharp kalkulezny cholecystitis]. Surgery. 2005; 5: 32-34.
  54. Petrova O. V., Bisalieva R. A., Nikulina D. M. Kompleksnaya laboratornaya ocenka vyrazhennosti vospalitel’nyh izmenenij pri obstruktivnom holecistite [Complex laboratory assessment of expressiveness of inflammatory changes at obstructive cholecystitis]. Bulletin of the Volgograd center Russian Academy of Medical Science and administration of the Volgograd region. 2006; № 2: 51.
  55. Halpin V. Acute cholecystitis. BMJ clinical evidence. ClinEvid. - 2014, № 8, P. 411.
  56. Kortram K., van Ramshorst B., Bollen T. L., Besselink M. G., Gouma D. J., Karsten T. Acute cholecystitis in high risk surgical patients: percutaneous cholecystostomy versus laparoscopic cholecystectomy (CHOCOLATE trial): Study protocol for a randomized controlled trial. Trials. 2012, № 13, P. 7.
  57. Rodríguez-Sanjuán J.C., Arruabarrena A., Sánchez-Moreno L., González-Sánchez F., Herrera L. A., Gómez-Fleitas M. Acute cholecystitis in high surgical risk patients: percutaneous cholecystostomy or emergency cholecystectomy? Am J Surg. 2012, № 204 (1), P. 54-9.
  58. Song S. H., Kwon C. I., Jin S. M., Park H. J., Chung C. W., Kwon S. W. Clinical characteristics of acute cholecystitis with elevated liver enzymes not associated with choledocolithiasis. Eur J Gastroenterol Hepatol, 2014, № 26, P. 452.
  59. Solomkin J. S., Mazuski J. E., Bradley J. S., Rodvold K. A., Goldstein E. J., Baron E. J. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Surg Infect (Larchmt). 2010, № 11 (1), P. 79-109.
  60. ZHurihin A.V., Kutukov V. E. Sistemnaya vospalitel’naya reakciya pri raznyh variantah techeniya ostrogo kal’kuleznogo holecistita [System inflammatory reaction at different options of a course of sharp kalkulezny cholecystitis]. Tsitokina and inflammation. 2011; 2: 28-31.
  61. Gadzhiev Dzh., Tagiev EH.N., Gadzhiev N. Dzh. Sravnitel’naya ocenka nekotoryh citokinov v syvorotke krovi i zhelchi u bol’nyh ostrym kal’kuleznym holecistitom [Comparative assessment of some tsitokin in serum of blood and bile at patients with sharp kalkulezny cholecystitis]. Surgery of Ukraine. 2013; 1: 62-65.
  62. Savel’ev V.S., Gel’fand B. R. Sepsis v nachale XXI veka. Klassifikaciya, kliniko-diagnosticheskaya koncepciya i lechenie. Classification, kliniko-diagnostic concept and treatment. Pathoanatomical diagnostics [Patologoanatomicheskaya diagnostika Sepsis at the beginning of the 21st century]: М.: Litterra, 2006: 109 р.

Full text is published :
Fedorov V. E., Zaharova N. B., Logvina O. A., Maslyakov V. V. Assessment of severity of the patient at sharp cholecystitis and mechanical jaundice in the light of national clinical recommendations (the review of literature). Experimental and Clinical Gastroenterology. 2019;163(3): 97–104. (In Russ.) DOI: 10.31146/1682-8658-ecg-163-3-97-104
Read & Download full text

1. EI of HE “The Surgut State University”, Surgut, Russia
2. Surgut District Clinical Hospital, Surgut, Russia
3. FSEBI of HE “The Ulianov Chuvash State University”, Cheboksary, Russia
4. Khanty-Mansiysk State Medical Academy, Khanty-Mansiysk, Russia

Keywords: chronic viral hepatitis, protein metabolism, liver fi brosis

Abstract: Purpose. To analysis of Russian and foreign literature about epidemiology, etiology and pathogenesis of chronic viral hepatitis B and C, including the factors that are likely to have effect on the progression of liver fibrosis, such as, condition of protein metabolism. Materials and methods. The literature data about this subject in the volume 58 sources of literature, 22 - Russian works and foreign - 36 was studied. Results and discussion. The most frequent factors that are likely to have effect on the progression of liver fibrosis, such as, etiology of chronic viral hepatitis B and C, combined viral pathology, features of the macrooganism, duration of infection, effect of alcohol and smoking were detected. The questions of the condition protein metabolism of chronic viral hepatitis B and C has been considered. Conclusion. The obtained data is different, because impact of the condition protein metabolism and other factors are important for learning and use in clinical practice with this pathology.

• References total 57 ⇓ :: .
  1. Ageyeva Ye.A., Alekseyenko S. A. Application of the oral «L-ornithine-L-aspartate» at hyperammoniemia at chronic liver diseases at precirrhotic stage. Clin. Prospekts Gastroenterol. Gepatol. 2015, no. 6, pp. 24-26.
  2. Bogomolov P. O., Buyeverov A. O., Uvarova O. V., Matsievich M. V. Hyperaamoniemia in Liver disease at precirrhotic stage: it is possible? Clin. Prospekts Gastroenterol. Gepatol. 2013, no.5, pp. 3-8.
  3. Golovanova E. V. Ammonia is an actual problem of the doctor and patient in therapeutic practice. Therapy. 2018, no.2, pp.49-55.
  4. Golovanova E. V. Endogenous ammonia as the reason of “circulus vitiosus” in progression of liver diseases. Pharmateca. 2017, no.6, vol.339, pp.1-7.
  5. Radzhiv D., Franchesco De Chiara, et al. Ammonia leads to pathological changes in hepatic stellate cells and it comes to be a goal in portal hypertension treatment. Journal of hepatology. 2016, vol. 64, pp. 823-833.
  6. Ivashkin V. T., Mayevskaya M. V. Modern principles of management of patient with chronic hepatitis B virus infection: Clinical value of the viral load level. Clinical Prospekts Gastroenterol. Gepatol. 2006, no.5, pp.17-24.
  7. Ilchenko L. Yu., Topcheeva O. N., Vinnitskaya E. V. Сlinical aspects of hepatic encephalopathyof patients with chronic liver disease. Consil. med. 2007. vol.9, no.1., pp. 12-13.
  8. Kuznetsova E. E., Gorokhova V. G., Dorofeev A. S. Role of the liver in the chemical homeostasis and liver detoxification function control using sample antipyrine. News of High School. Applied chemistry and biotechnology. 2014, no.2, vol.7, pp.58-62.
  9. Litvitsky P. F., Mal’tseva L. D. Protein, Amino Acids and Nucleic Acids Metabolism Disorders. Questions of modern pediatrics. 2015, no.14, vol.1, pp. 95-107.
  10. Nadinskaya M. Yu. Treatment of hepatic encephalopathy in patients with cirrhosis from the standpoint of evidence-based medicine: myths and reality. Consil. Med. 2006, book 8, no.1, pp.17-28.
  11. Pavlov Ch. S., Ivashkin V. T. Evaluate and reduce the risk of fibrosis, cirrhosis and hepatocellular carcinoma in patients with chronic infection with hepatitis B and C viruses. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2007, book 17, no.5, pp.16-24.
  12. Podymova S. D., Azov A. G. Viral hepatitis in elderly patients. Features of epidemiology, clinical picture, prevention and treatment. Viral hepatitis: achievements and prospects.2001, no.1, pp. 3-4.
  13. Rachkovsky M. I., Beloborodova E. I., Beloborodova E. V. et al. Clinical aspects of liver cirrhosis progression. Russian Journal of Gastroenterology, Hepatology and Coloproctology. 2007, book 17, no.5, app. 30, p. 93.
  14. Russkikh A. V. Modern methods of diagnosis of viral hepatitis. Archive of the journal Farmateka. 2013, no.14.
  15. Prognostic value of combination allelic gene variants of cytokines and hemochromatosis in patients with chronic liver diseases. Russian Journal of Gastroenterology, Hepatology and Coloproctology. 2007, book 17, no.2, pp.50-56.
  16. Severin E. S. Biochemistry, Geotar -Media. 2004, pp. 784
  17. Serov V. V. Virus and host factors in the development and progression of chronic viral hepatitis B and C. Russian Journal of Gastroenterology, Hepatology and Coloproctology. 2006, no. 4, pp. 12-23.
  18. Usmanova N. R. Clinical and laboratory features and comparative assessment of damage to the health of the population of Kyrgyzstan from chronic liver damage: dissertation of the candidate of medical science: 14.00.05
  19. Serova V. V., Aprosina Z. G. Chronic viral hepatitis. Moscow. Medicine Publ., 2004, 384 p.
  20. Chuyelov S. B. Factors affecting the progression of fibrosis and the formation of cirrhosis in chronic viral hepatitis. Childhood infections. 2007, no.4, pp.34-40
  21. Sherlock S., Dooley J. Diseases of the liver and biliary tract: Trans. from English. Moscow, Geotar Medicine, 1999.
  22. Amodio P. The liver, the brain and nitrogenmetabolism. Metab Brain Dis.,2009, 24: 1.
  23. Ardalan F. A., Osquei M. R., Toosi M. N., Irvanloo G. Synergic effect of chronic hepatitis С infection and beta thalassemia major with marked hepatic iron overload on liver fibrosis: a retrospective cross-sectional study. BMC-Gastroenterol. 2004.V. 4. P. 17.
  24. Bajaj J.S., Pinkerton S. D., Sanyal A. J., Heuman D. M. Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis. Hepatology, 2012 April, № 55(4):1164-71.
  25. Benyon R.C. and Iredale J. P. 2000. Is liver fibrosis reversible? Gut. 46:443-446. 3 Arthur, M.J. 2000. Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol. 279: G245-G249. Arthur, M.J. 2002. Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. Gastroenterology. 122:1525-1528.
  26. Bernal W, Hall C, Karvellas CJ et al. Arterial ammonia and clinical risk factors for encephalopathy and intracranial hypertension in acute liver failure// Hepatology, 2007, 46: 1844-1852.
  27. Blei AT. Hepatic encephalopathy in acute liver failure. In: Haussinger D, Kircheiss G, Schliess F, editors. Hepatic encephalopathy and nitrogen metabolism. London-Heidelberg: Springer. 2006: 433-441.
  28. Bosoi CR, Rose CF. Identifying the direct effects of ammonia on the brain. Metab Brain Dis. 2009, 24: 95-102.
  29. Cordoba J, Lopez-Hellin J, Planas M et al. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. J Hepatol. 2004, 41: 38-43.
  30. D’Souza R. F. et al. Relationship between serum ferritin, hepatic iron staining, diabetes mellitus and fibrosis progression in patients with chronic hepatitis C /R. F. D’Souza et al. Aliment. Pharmacol. Ther. - 2005. - V. 21. - P. 519-524.
  31. Fontaine H. et al. Hepatitis activity index is a key factor in determining the natural history of chronic hepatitis C / H. Fontaine et al. Hum. Palhol. - 2001. - V. 32. - P. 904-909
  32. Geier A. et al. Common heterozygous hemochromatosis gene mutations are risk factors for inflammation and fibrosis in chronic hepatitis С / A. Geier et al. Liver Int. - 2004. - V. 24. - P. 285-294.
  33. GhallabА., Cellière G., Henkel S. G. et al. Model-guided identification of a therapeutic strategy to reduce hyperammonemia in liver diseases. Hepatology. 2016; 64: 860-871
  34. Hadjihambi A., Arias N., Mohammed Sh., Jalan R. Hepatic encephalopathy: a critical current review. Hepatol. Int. 2018; 2018; 2: 135-147.
  35. Hassinger D., Steeb R., Gerok W. Ammonium and bicarbonate homeostasisin chronic liver disease. Klin. Wochenschr. 1990; 68: 175-182
  36. Hezode C. et al. Impact of smoking on histological liver lesions in chronic hepatitis С / C. Hezode et al. Gut. - 2003. - V. 52. - P. 126-129
  37. HuZ., LiuY., ZhaiX., DaiJ., JinG., et al. New loci associated with chronic hepatitis B virus infection in Han Chinese. Nat Genet. 2013 Dec; 45(12): 1499-503. doi: 10.1038/ng.2809. E pub 2013 Oct 27.
  38. Jalan R., De Chiara F., Balasubramaniyan V. et al. Ammonia produces pathological changes in human hepatic stellate cells and is a target for therapy of portal hypertension. J Hepatol. 2016; 64(4): 823-833.doi: 10.1016/j.jhep.2015.11.019. Epub 2015 Dec 2.
  39. Kaiser S., Gerok W., Haussinger D. Ammonia and glutamine metabolism in human liver slices: new aspects on the pathogenesis of hyperammonaemia in chronic liver disease. European Journal of Clinical Investigation. 1988; 18: 535-542.
  40. Kumar R, Bhatia V. Structured approach to treatpatients with acute liver failure: a hepaticemergency. Indian J Crit Care Med. 2012, 16: 1-7.
  41. Laleman W, Verbeke L, Meersseman P et al. Acuteon-chronic liver failure: current concepts on definition, pathogenesis, clinical manifestations andpotential therapeutic interventions. Expert RevGastroenterolHepatol, 2011, 5: 523-537.
  42. Li S., Deng Y., Chen Z. P., Huang S., Liao X. C., Lin L. W., et al. Genetic polymorphism of interleukin-16 influences susceptibility to HBV-related hepatocellular carcinoma in a Chinese population. Infection. Genetics and Evolution. 2011 Dec; 11 (8): 2083-8. DOI: 10.1016/j. meegid. 2011.09.025. Epub 2011 12.
  43. Mc Glynn KA, London WT. Epidemiology and natural history of hepatocellular carcinoma. Best Pract Res ClinGastroenterol. 2005;19:3-
  44. Ortiz V. et al. Contribution of obesity to hepatitis C-related fibrosis progression / V. Ortiz et al. Am. J. Gastroenterol. - 2002. - V. 97. - P. 2408-2414.
  45. Parekh PJ, Balart LA. Ammonia and its role inthe pathogenesis of hepatic encephalopathy. Clin Liver Dis, 2015, 19: 529-537.
  46. Perazzo JC, Tallis S, Delfante A. Hepatic encephalopathy: an approach to its multiple pathophysiologicalfeatures. World J Hepatol, 2012, 27: 50-65.
  47. Rioux KP, Sharkey KA, Wallace JL, Swain MG. Hepatic mucosal mast cell hyperplasia in rats with secondary biliary cirrhosis. Hepatology. 1996; 23: 888-895
  48. Sagnelli E. et al. Liver histology in patients with HBsAg negative anti-HBc and antiHCV positive chronic hepatitis / E. Sagnelli et al. J. Med. Virol. - 2005. - V. 75. - P. 222-226
  49. Shura R.D., Brearly T. W., Rowland J. A. et al. Send to RBANS validity indices: a systematic review and Meta-Analysis. Neuropsychol. Rev.2018 May 16. doi: 10.1007/s11065-018-9377-5
  50. Silva G. F., Nishimura N. F., Coelho K. I., Soares E. C. Grading and staging chronic hepatitis С and its relation to genotypes and epidemiological factors in Brazilian blood donors / G. F. Silva, N. F. Nishimura, K. I. Coelho, E. C. Soares. Braz. J. Infect. Dis. - 2005. - V. 9. - P. 142-149.
  51. Simmonds P. et al. Epidemiological, clinical and therapeutic associations of hepatitis C types in western European patients / P. Simmonds et al. J. Hepatol. - 1996. - V. 24. - P. 517-524
  52. Suraweera C., Anandakumar D., Dahanayake D. et al. Validation of the Sinhala version of the Repeatable Battery for Assessment of Neuropsychological Status (RBANS). Ceylon Med. J. 2016;61(4): 167-170.
  53. Tranah T.H., Paolino A., Shawcross D. L. Pathophysiological Mechanisms of Hepatic Encephalopathy. Clinical Liver Disease. 2015
  54. Vaquero J, Polson J, Chung C et al. Infection andthe progression of hepatic encephalopathy inacute liver failure. Gastroenterology, 2003, 125:755-764
  55. Vilstrup H., Amodio P., Bajaj J. et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. J. Hepatol. 2014; 60: 715-735.
  56. Walker V. Severe hyperammonaemia in adults not explained by liverdisease. Annals of Clin. Biochemistry. 2012; 49: 214-228.
  57. Zarski J. P. et al. Rate of natural disease progression in patients with chronic hepatitis C / J. P. Zarski et al. J. Hepatol. 2003.V. 38.P. 307-314.

Full text is published :
Tarasova L. V., Ariamkina O. L., Volkova T. V., Busalayeva E. I., Sosnovskaia E. V. Protein metabolic disorders in chronic viral hepatitis. Experimental and Clinical Gastroenterology. 2019;163(3): 105–112. (In Russ.) DOI: 10.31146/1682-8658-ecg-163-3-105-112
Read & Download full text